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ABSTRACT 
 
The Impacts of Sex and Myogenic Cell Transplantation on Collateral Capillary Arteriogenesis 
 
Padon Mary Sivesind 
 
Current treatments for peripheral arterial occlusive disease (PAOD) have limited success, so there is a 
need to develop more effective treatments. Because patients with native collaterals have a better 
prognosis, promoting collateral arteriogenesis is a potential PAOD treatment. Additionally, female PAOD 
patients have a worse response to treatment and a worse prognosis compared to males, which could be 
due to impaired collateralization. Cell transplantation is a potential treatment option to promote collateral 
arteriogenesis. Bone marrow derived stem cells are the main cell type that has been investigated, but they 
have had limited clinical success. Delivering a stem cell type native to the tissue like myogenic stem cells 
could have improved outcomes. In this study, the lateral spinotrapezius feed artery was ligated in male 
and female Balb/C mice to induce collateral capillary arteriogenesis, and 7 days post ligation arterialized 
collateral capillary (ACC) number and diameter were determined. There were no differences between 
sexes, which could be because young, healthy mice were used in this study rather than aged and diseased 
models. Because we observed no sex differences, we then assessed the effect of myogenic cell 
transplantation in male mice only. Immediately following ligation of the spinotrapezius feed artery, mice 
were treated with myogenic cells, thrombin, or vehicle, and 7 days post ligation ACC number and 
diameter were determined. Thrombin increased ACC number, but myogenic cells had no effect. However, 
myogenic cells increased ACC diameter, and both myogenic cells and thrombin decreased ACC number 
in the region of the muscle with the largest collateral, and increased the maximum ACC diameter. 
Another factor that could affect ACC formation is a pre-existing collateral (PEC), which only some 
Balb/C mice have, so we also separated mice into PEC and non-PEC groups for analysis. In mice with a 
PEC, thrombin increased ACC number, and both myogenic cells and thrombin increased ACC diameter. 
There was a trend toward smaller arterialized capillaries in mice with a PEC, which could be because the 
majority of the blood flow is redirected through the PEC, so the PEC was the main vessel to remodel.  
These results are consistent with previous studies that indicated that thrombin augments arteriogenesis as 
well as increasing V-CAM, and suggest that myogenic cells have a similar effect possibly by secreting 
arteriogenic factors such as VEGF and MMPs. Because myogenic cells increase arteriogenesis, and 
macrophages are an essential regulator of arteriogenesis, we also tested the hypothesis that myogenic cells 
would increase macrophage content. Macrophage number increased with ligation, but there was no 
difference in macrophage number between any of the treatment groups. The lack of difference in 
macrophage number could be because the day 7 timepoint was too late, as macrophage content peaks at 
day 3. Because myoblasts increased arteriogenesis, they also may have increased the number M2 
macrophages, which are the main macrophage contributor to arteriogenesis, but we used a general 
macrophage marker and could not detect an increase in M2 macrophages. In future studies, to determine 
if there is an increase in M2 macrophages a stain specific to M2 macrophages like CD206 could be added. 
Additionally, a diabetic Balb/C strain could be used to determine if arteriogenesis is impaired in males 
compared to females in a diseased model. 
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 1 
INTRODUCTION 
Peripheral arterial occlusive disease (PAOD) affects 8 to 12 million people in the United States 
and can lead to critical limb ischemia (CLI) and amputation [1]. Current treatments include stenting and 
bypass grafting (Figure 1), but only 50% of CLI patients are eligible, and after 1 year, only 25% of 
revascularization attempts in these patients are successful [2]. Amputation is the only option for ineligible 
patients, and within 6 months, about 40% of ineligible patients have a limb amputated and 20% die [2]. 
The insufficiency of current treatments suggests that promoting collateral arteriogenesis may be a 
desirable treatment option. Collaterals are anastomoses between two arterioles that provide an alternative 
route for blood flow to bypass an arterial occlusion. Patients with pre-existing collaterals in their coronary 
circulation have better myocardial viability, a reduced risk for a repeat cardiac event, and a lower hospital 
mortality rate following heart attack or revascularization [3,4,5]. In the peripheral circulation, a well-
developed collateral circulation improves 6 minute walk test results, and slows performance decline over 
time [6,7]. Unfortunately, not all humans have a native collateral network, and about 30% of patients 
never develop angiographically-identifiable collaterals [8,9].  
 
Figure 1. Current Treatments for PAOD. A) Both bypass grafting (left) and inserting a bypass vein (right) 
are common treatments for PAD to allow bloodflow around the occlusion. Adapted from [10] B) Stenting 
is also used to reopen the occluded artery. Adapted from [11] 
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Similar to humans, animals also have varying degrees of collateral formation in response to an 
occlusion. For example, mice from the C57Bl/6 strain have many pre-existing collaterals that readily 
enlarge, while mice from the Balb/C strain have fewer pre-existing collaterals that have impaired 
enlargement [12]. When pre-existing collaterals are present, an occlusion causes the pressure gradient to 
increase across the collateral, which elevates blood flow, increases the shear stress, activates endothelial 
cells, and leads to macrophage recruitment [13,14]. Macrophages secrete matrix metalloproteinases to 
degrade the matrix, while endothelial cells and smooth muscle cells proliferate in response to growth 
factors secreted by macrophages and expand the arterial diameter until the shear stress is normalized 
(Figure 2) [13,14]. In tissues of Balb/C mice without pre-existing arteriolar collaterals, an arterial 
occlusion causes arterialization in capillaries that connect ischemic an non-ischemic terminal arterioles 
[15]. These collateral capillaries outwardly remodel and gain a smooth muscle cell layer either by 
recruiting smooth muscle cells from an upstream vessel or through perivascular cell differentiation [15].  
 
Figure 2. Collateral arteriogenesis. Before an occlusion, blood flows through both arterioles and there is a 
limited pressure gradient through the collaterals (left). Following an occlusion (grey), blood flow is blocked 
in one of the arterioles, and the pressure gradient in the collaterals increases, which leads to elevated blood 
flow and increased shear stress and remodeling in the collateral vessels (right). Adapted from Heil et al [16]. 
 
The first approach to target arteriogenesis as a treatment for PAOD involved delivering single 
factors known to contribute to arteriogenesis, which were injected either intramuscularly in the limb 
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requiring treatment or intravenously in a major vein [17,18]. The factors investigated included VEGF, 
FGF and HGF as both gene and protein therapy, and the transcription factor HIF-1α as gene therapy 
[17,18,19,20,21]. In early clinical studies and animal models, VEGF, FGF, HIF-1α and HGF effectively 
increased perfusion, ulcer healing, and limb salvage [17,18,19,20,21]. However, when these factors were 
tested in larger blinded, randomized controlled trials, the treatments had no effect on end points such as 
ankle-brachial index, rest pain, exercise performance, or ulcer healing [22,23,24,25,26]. 
The failure of single factor treatments led to the investigation of cell transplantation to stimulate 
arteriogenesis as a treatment for PAOD. Because arteriogenesis signaling involves multiple growth 
factors, delivering cells as a treatment may be more effective than delivering a single growth factor 
[27,28]. The first cell type investigated was bone marrow mononuclear cells (MNCs). In early clinical 
trials, intramuscular injections of bone marrow MNCs increased ulcer healing and amputation free 
survival, but had no effect on limb perfusion, pain free walking distance or ankle-brachial index 
[29,30,31]. These results were positive enough to perform larger clinical trials, but in randomized 
controlled trials, bone marrow MNCs had no effect on amputation rate, ankle-brachial index or ulcer 
healing [32,33,34]. Another limitation with bone marrow MNCs is that they cannot be cultured once 
isolated, and therefore a large volume of bone marrow must be obtained [35]. However, another bone 
marrow derived cell, bone marrow mesenchymal stem cells (MSCs), requires significantly less bone 
marrow because the cells remain potent when expanded after isolation [36]. Bone marrow MSCs also 
increased perfusion in the rat hindlimb more than bone marrow MNCs [37], but similar to bone marrow 
MNCs, they have had mixed clinical outcomes. When injected into the heart, bone marrow MSCs had no 
effect on left ventricle function at 18 months [38]. Additionally, intramuscular injections of bone marrow 
MSCs lead to a trend towards reduced amputation rates and rest pain, but had no effect on ankle brachial 
index [39,40]. Even though bone marrow cells have shown some promise in the clinic, they must be 
isolated through a bone marrow biopsy which can be painful for the patient and sometimes requires 
general anesthesia [41,42]. Isolation of endothelial progenitor cells (EPCs), another potential treatment 
for PAOD, is less painful than a bone marrow biopsy. EPCs can be isolated from the peripheral blood 
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after dosing with granulocyte colony stimulating factor (G-CSF), which stimulates EPCs migration into 
the blood [43]. In non-placebo controlled clinical trials, intramuscular injections of EPCs increased partial 
oxygen pressure and pain free walking distance and decreased ulcer size, but there was no difference in 
ankle brachial index [43,44]. When a placebo control was used, there was a trend towards a lower 
amputation rate at 6 and 12 months but no difference in ankle brachial index, pain free walking distance, 
or wound healing [45].  
Although bone marrow-derived cells do not appear to be a viable alternative to revascularization 
treatments, exercise is already a successful PAOD treatment. Exercise treatment is as good or better than 
revascularization as a treatment for PAOD [46,47], and regimes that include eccentric contractions had 
increased walking ability [48]. However, exercise treatment is only effective when performed under 
supervision [49,50]. Therefore, a potential treatment for PAOD is delivering a cell type that is activated 
during eccentric exercise such as satellite cells [51]. Satellite cells recruit monocytes in response to 
muscle injury [52,53], and macrophages are more efficient at paracrine signaling in muscle tissue when 
satellite cells are present [54]. Satellite cells also have angiogenic properties [55,56], but their effect on 
arteriogenesis has not been investigated. Additionally, tissue resident stem cells may have an advantage 
over other cell types because they may be able to communicate within the ‘myo-vascular’ niche more 
effectively than non-tissue resident stem cells. For example, tissue resident mesenchymal stem cells more 
effectively differentiate into muscle and cartilage than bone marrow derived mesenchymal stem cells 
[57,58,59]. The stem cell niche is important in maintaining stem cell properties including how they 
communicate with surrounding cells [60,61]. Therefore, bone marrow-derived cells, which have been 
removed from their niche, may communicate less effectively within the ‘myo-vascular’ niche than tissue 
resident stem cells, which could potentially contribute to their reduced efficacy as a revascularization 
treatment. Another advantage of muscle derived stem cells is that the isolation only requires a muscle 
biopsy [62,63] rather than additional treatment with G-CSF that is required to isolate EPCs or a bone 
marrow biopsy that is required to isolated bone marrow MSCs and MNCs. 
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To develop effective new PAOD treatments, differences in efficacy of current treatments must be 
understood so new treatments do not have the same weaknesses. For example, women do not seem to 
respond to treatment as well as men. There is a higher incidence of wound complications after bypass 
grafting in women [64], a higher rate of hospital mortality [65], and less positive results from exercise 
treatment than in males [66]. Additionally, females with PAOD appear to have a worse prognosis than 
males, with a shorter walking distance [67], and a higher rate of critical limb ischemia [68]. The sexual 
dimorphism seen in humans could be explained through investigation of processes related to PAOD in 
animal models. For example, bone marrow MNCs reduce aortic plaque in male, but not female, ApoE-/- 
knockout mice [69]. Impaired collateralization could be another cause of the clinical difference between 
males and females. In patients with an occluded coronary artery, females were less likely than males to 
have an angiographically identifiable collateral [70], suggesting that arteriogenesis might be impaired in 
females. Since the number of female patients with PAOD is at least equal to the number of males [71], 
and the number of women with the PAOD is expected to increase [72], it is important to understand any 
sex differences so women with PAOD can be treated effectively. 
In summary, clinically, females appear to have a worse prognosis and response to treatment than 
males, which could be due to impaired collateralization in females. Additionally, myogenic stem cells 
have angiogenic properties [55,56], but their effect on arteriogenesis is unknown. Therefore, we tested the 
hypotheses that collateral capillary arteriogenesis is impaired in females compared to males, and that 
myogenic cell transplantation would enhance collateral capillary arteriogenesis and macrophage 
recruitment. To support the second hypothesis, we developed a gelatin hydrogel to use as a vehicle for 
myogenic cell transplantation.  
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METHODS 
Animals 
Male and Female Balb/C mice (Taconic Farms; Oxnard, CA and Jackson Labs; Sacramento, CA) 
between 8 and 14 weeks, and Male ICR mice (Cal Poly Vivarium) were housed 2 to 4 mice per 
microisolator cage with ad libetum access to food and water, plus enrichment (a mouse ‘house’ and a 
plastic tube). The cages were in a temperature controlled room with a 12-hour light/dark cycle. The male 
ICR mice were used during gelatin vehicle testing; Balb/C mice were used for all other experiments. To 
determine if collateral capillary arteriogenesis is impaired in females, mice were divided into male (n=8) 
and female (n=8) groups. For the myogenic cell transplantation study, only male mice were used. Mice 
were divided into 4 groups: myogenic cells (n=6), vehicle (n=6), thrombin (n=6), and ligation only (n=6). 
All procedures were approved by the California Polytechnic University Institutional Animal Care and Use 
Committee. 
Ligation 
Animals were anesthetized in an induction chamber with 5% isofluorane in oxygen flowing at 3 
l·min-1.  After anesthetization, isofluorane was reduced to 1-3% flowing at 0.5 – 1.0 l·min-1. Prior to 
surgery, trimming clippers and depilatory cream were used to remove hair from the dorsal area of the 
mouse, which was then disinfected with chlorohexidine diacetate (Nolvasan). Animals were maintained at 
35°C during surgery with a heat pad and a rectal temperature probe, and ophthalmic ointment was applied 
to the cornea to prevent desiccation. A small incision was made parallel to the spine over the lateral edge 
of the spinotrapezius. The fat pad overlying the spinotrapezius was undermined using blunt dissection to 
expose the fat pad underlying the lateral edge of the muscle that contains the feed artery/vein pair. The 
artery was separated from the vein, and two single strands from 6-0 silk suture were passed under the 
artery. The sutures were tied around the artery in two locations, and the artery was transected between the 
two sutures before closing the incision using 7-0 prolene suture. On the sham side, the same procedure 
was repeated up to the separation of the artery from the vein. 
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In animals receiving either myogenic cells or vehicle, the spinotrapezius was undermined by 
gentle blunt dissection to create a pocket for placing the cell construct or the vehicle (Figure 1). A 
cylinder of the cell construct was removed with a 1.5mm biopsy punch and inserted into the pocket. For 
mice receiving thrombin, 1µL·g-1 body weight of thrombin (1 NIH unit/µL) was superfused superficially 
and injected deep to the muscle following ligation (Figure 3).  
 
 
 
Figure 3. Location of treatment delivery. Following ligation of the feed artery, the 
spinotrapezius was undermined in the location shown (black arrow) by gentle blunt 
dissection to create pocket for placing the cell construct or the vehicle. For thrombin 
treatment delivery, 1uL·g-1 body weight of thrombin (1 NIH unit/µL) was superfused 
above and injected below the muscle in the location shown (grey area). 
 
Gelatin Preparation 
 
A 10% gelatin solution was prepared aseptically in an Erlenmeyer flask in a biological safety 
cabinet. On a hot plate outside the biological safety cabinet, the solution was boiled for 5 minutes to 
sterilize and solubilize the gelatin. After boiling, the gelatin solution was transferred to a 24 well plate and 
stored at room temperature until it polymerized. After polymerization, the gelatin was cross-linked with 
6mM 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and stored overnight at 4°C. After storage, 
the gels were washed 3 times for 30 minutes with PBS. 
Myoblasts isolated from Balb/C mice were dissociated with a Cell Dissociation Buffer (EDTA, 
ThermoFisher, Waltham, MA), centrifuged at 300g for 5 minutes, suspended in growth media (20% FBS, 
2µl/ml media bFGF (1µg/ml), 2µl/ml media SB 203580 (10mmol) in Hams F-10 Nutrient Mixture with 
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1% Pen/Strep), and 100,000 cells were sodded onto one well of gelatin so that approximately 9.6 x 103 
cells would be transplanted in the 1.5mm diameter punch. Gelatin vehicles were stored in the incubator 
overnight to allow for cell adhesion.  
Gelatin Testing 
 
Both 4% and 10% gelatin vehicles were prepared aseptically in a 24-well plate. After 
polymerization, vehicles were cross-linked with either 6mM or 12 mM EDC. Gelatin vehicles without 
cross-linker were also prepared through a similar procedure, without the addition of EDC. The vehicles 
were incubated overnight at 4°C to allow for crosslinking and washed 3 times for 30 minutes with 
phosphate buffered saline (PBS) after storage. For acute testing, vehicles were either implanted deep to 
the spinotrapezius or stored in the incubator overnight to determine which vehicle types remained 
polymerized at 37ºC. To test the cytotoxicity of cross-linked gelatin, 3T3 fibroblasts were sodded onto 
each vehicle type. Cell morphology was observed 1, 3, and 12 hours after sodding. To test vehicle 
retention, both 4% and 10% vehicles cross-linked with 6mM EDC were implanted deep to the 
spinotrapezius (n=2). After seven days, the spinotrapezius was resected to determine if the vehicle 
remained in place.  
Perfusion Fixation 
 
At 7 days following ligation, mice were perfusion fixed with paraformaldehyde in preparation for 
immunofluorescence. Prior to fixation, overlying fascia was removed from the spinotrapezius muscles. 
Through a thoracotomy, a catheter was placed in the left ventricle, and 40 mL of vasodilator solution (10-3 
SNP, 10-4 adenosine, and 1 U/ml heparin in PBS) was perfused through the circulation at 2 ml·min-1 using 
a syringe pump to displace the blood and maximally dilate the vasculature. Then 5 mL of 4% 
paraformaldehyde (PFA) was perfused at 1 ml·min-1 to fix the tissue. Following fixation, spinotrapezius 
muscles were undermined, resected, and underlying fascia was removed. Muscles were post-fixed 
overnight in 4% PFA at 4°C and then transferred to PBS and stored at 4°C until staining.  
 
 9 
Staining and Imaging 
 
To determine arterialized collateral capillary (ACC) diameter, number, and smooth muscle cell 
coverage, the spinotrapezius muscles were stained with 1:200 1A4 clone alpha-smooth muscle actin 
(smooth muscle cells, Cy3, Sigma-Aldrich 1mg/mL) and 1:20 Isolectin GS-IB4 from GRI (endothelial 
cells, Alexa Fluor 647, Thermo Fisher Scientific 1 mg/mL). To determine macrophage number, 
spinotrapezious muscles were stained with 1:100 CD68 FA-11 Clone (macrophages, Alexa Fluor 488, 
Bio-Rad 0.05 mg/mL), which is a lysosomal/endosomal-associated membrane glycoprotein that is 
expressed on lysosomes and endosomes [73]. All antibodies were prepared in PBS with 0.1% Triton X-
100 and 2% BSA, and incubated at 4°C for 72 hours. The muscles were then washed 3 times for 20 
minutes with 0.1% Triton X-100 in PBS, and then for 30 minutes in PBS. Muscles were mounted on glass 
slides in a 50:50 PBS:glycerol solution. 
Using a 20x objective on a confocal microscope (Olympus FV 1000, Olympus, Center Valley, 
Pennsylvania), three regions were imaged between ischemic and perfused arteriolar trees, where ACCs 
are located in operated muscle (Figure 4). To find the appropriate imaging area, the ischemic arteriolar 
tree was followed down to a terminal arteriole where ACCs were identified because they are similar in 
appearance to capillaries, but they are also surrounded by smooth muscle cells. Unlike typical capillaries, 
ACCs connect two terminal arterioles, are relatively straight, and their long axis is parallel to the muscle 
fibers. On the sham side, the appropriate imaging location was found by following the arteriolar tree that 
would be the ischemic tree in the operated muscle to a terminal arteriole until there was also a terminal 
arteriole from a different arteriolar tree in the field of view. At each location, a 150µm thick z-stack with 
5µm thick slices was obtained.  
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Figure 4. Location of Imaging Regions. Each spinotrapezius muscle was imaged using a 20x objective on a 
confocal microscope. The muscles were imaged at three locations between arteriolar trees (red squares) where ACCs 
are located on ligated muscles. Red staining is alpha-smooth muscle actin. Blue staining is lectin. Scale bar on 
montage is 1mm. Scale bars on regional images are 50µm. Figure adapted from Mac Gabhann et al [15]. 
 
Image Analysis 
 
To determine the number and diameter of capillaries and ACCs, the z-stacks were compressed 
and the channels were separated using ImageJ software. Alpha-smooth muscle positive vessels (ACCs) 
and lectin positive vessels (capillaries) were counted in a 200 µm2 region in the compressed image. Inner 
diameters of three alpha-smooth muscle positive vessels and lectin positive vessels were also measured in 
each region.  
To determine the maximum ACC diameter, the diameter of the largest collateral was measured in 
each replicate. To determine ACC number in the region of the largest collateral, all alpha-smooth muscle 
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actin positive vessels were counted along a line drawn perpendicular to the ACCs in the region with the 
largest collateral. 
CD68 positive cells were counted by finding large oval or elliptical areas of that were oriented 
around an ACC. To determine overall macrophage number, CD68 positive cells were counted within the 
same 200 µm2 region as the ACCs. To determine vessel associated macrophage number, CD68 positive 
cells that were within 50 µm2  of an ACC were counted along the entire length of the ACC.  
Data Analysis 
 
Differences in vessel number and diameter in males and females and in ligated and sham muscles 
were determined by independent t-tests. Differences in number and diameter of vessels in the four groups 
(myogenic cells, vehicle, thrombin, and ligation only) and in ligated and sham muscles were determined 
using One-Way ANOVA. 
Differences in maximum diameter and ACC number in the four groups (myogenic cells, vehicle, 
thrombin, and ligation only) and in ligated and sham muscles were determined using One-Way ANOVA. 
Differences in number of CD68 positive cells in the four groups (myogenic cells, vehicle, thrombin, and 
ligation only) and in ligated and sham muscles were determined using One-Way ANOVA. Data are 
presented as mean ± SE. 
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RESULTS 
 
Female versus Male Collateral Capillary Arteriogenesis 
 
To test the hypothesis that collateral capillary arteriogenesis is impaired in female mice as 
compared to male mice, we used confocal microscopy (Figure 5) to count and measure the diameters of 
collateral capillaries and arterialized collateral capillaries (ACCs) that connect ischemic and perfused 
arteriolar trees.  
 
Figure 5. Confocal images of arterialized collateral capillaries. Confocal images were taken of ACCs between 
the ligated arteriolar tree and an adjacent, perfused arteriolar tree using a 20x objective. (A,D) Alpha-smooth muscle 
actin positive vessels show arterioles and ACCs. (B,E) Lectin positive vessels show both capillaries and ACCs. 
(C,F) A composite image combining A and B or E and F. A-C are from an operated muscle and D-F are from a 
sham muscle. Scale bars are 50µm. 
 
There was no difference in the overall number of vessels between male and female mice or 
between ligated and sham muscles (10.8 ± 0.4 female operated, 11.2 ± 0.3 female sham, 11.6 ± 0.6 male 
operated, 11.8 ± 0.5 male sham). To determine the number of ACCs, we counted the number of alpha-
smooth muscle actin positive vessels in the capillary position. As expected, the number of alpha-smooth 
muscle actin positive vessels increased in operated muscles (zero for both male and female sham, 4.6 ± 
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0.1 female operated, 4.9 ± 0.1 male operated). Additionally, there was a trend (p = 0.08) towards an 
increase in presumptive ACCs in males (Figure 6), but qualitatively it did not seem like there was a 
difference between males and females. There	was	also	limited	variation	in	ACC	number	between	imaging	
regions,	which	suggests	that	3	regions	were	sufficient	for	imaging. 
 
 
Figure 6. No difference in number of alpha-smooth muscle positive vessels between males and females. 
Capillaries and ACCs were counted between ischemic and perfused arteriolar trees on both male (n=6) and female 
(n=5) replicates at day 7 using a 20x objective on a confocal microscope. The number of alpha-smooth muscle actin 
positive vessels increased in operated muscles. There was no difference between males and females in the number of 
ACCs. There was also no difference between males and females or ligated and sham in capillary number. (*, p<0.05 
for operated versus sham) 
 
As expected, ACCs had a larger diameter (10.8 ± 0.5 µm in females and 11.2 ± 0.3 µm in males) 
than capillaries (4.7 ± 0.2 µm in females and 4.6 ± 0.1 µm in males), indicating outward remodeling 
occurred, but there was no difference in male and female ACC diameter or in capillary diameter between 
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ligated and sham muscles (Figure 7). There was also limited variation in ACC diameter between imaging 
regions, which suggests that 3 regions were sufficient for imaging. 
 
Figure 7. No difference between males and females in arterialized collateral capillary diameter. Capillary 
diameter and ACC diameter were measured between ischemic and perfused trees on both male (n=6) and female 
(n=5) replicates at day 7 using a 20x objective on a confocal microscope. Alpha-smooth muscle actin positive 
vessels had an increased diameter compared to capillaries. There was no difference between males and females in 
ACC diameter. There was also no difference between males and females or ligated and sham in capillary diameter. 
(*, p<0.05 for alpha-smooth muscle actin positive vessels versus capillaries) 
 
Gelatin Vehicle for Cell Transplantation 
 
Because there was no difference in collateral capillary arterialization in males and females, we 
evaluated the ability of myogenic cell transplantation to augment arteriogenesis only in male mice. 
Myogenic cell transplantation is a potential solution to the need for improved PAOD treatments. Previous 
cell transplantation attempts in our laboratory utilized type I rat tail collagen as the vehicle. 
Unfortunately, rat-tail collagen polymerized inconsistently- in some instances, the vehicles polymerized 
easily, while in others no polymerization ever occurred (unpublished observations). Therefore, to 
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transplant myogenic cells in the spinotrapezius, we needed to develop a more consistent cell vehicle. 
Gelatin was chosen as the vehicle material because it was easy to prepare, inexpensive, and biocompatible 
[74]. A gelatin solution was prepared, heated aseptically and then aliquoted into a 24-well plate for 
polymerization.  
In addition to developing a protocol for sterile gelatin preparation, we also developed the vehicle 
composition. The first two iterations of the vehicle, 4% and 10% gelatin vehicles, depolymerized 
immediately when implanted beneath the spinotrapezius. Therefore, we added a crosslinking agent (1-
Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC)) to gelatin preparations. To test the cross-linked 
gelatin acutely, both 4% and 10% gelatin vehicles cross-linked with either 6mM or 12mM EDC were 
incubated overnight at 37°C with 5% CO2; all vehicles remained polymerized. Since both cross-linker 
concentrations remained polymerized, 6mM EDC was used in subsequent vehicle preparation to 
minimize the amount of cross-linker. With crosslinking maintaining gelatin polymerization, vehicles (4% 
and 10% gelatin cross-linked with 6mM EDC) were implanted deep to the spinotrapezius for 7 days (n = 
2). After 7 days only the 10% gelatin vehicles remained polymerized, and there were no signs of infection 
or inflammation (Figure 8). Thus, we continued using the 10% gelatin cross-linked with 6mM EDC as the 
cell transplantation vehicle. 
 
Figure 8. Cross-linked gelatin vehicle remained polymerized for 7 days in vivo. (A) Gelatin vehicles were 
punched with a 1.5mm biopsy punch and implanted under the spinotrapezius. (B) Seven days later, the 
spinotrapezius was excised and the vehicle (white arrow) was still intact and there was no infection or inflammation. 
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Finally, to assess the cytotoxicity of the cross-linked gelatin, we seeded them with fibroblasts and 
cultured for 12 hours, which is the same duration the myogenic cells would be cultured on the vehicle 
before transplantation. The 12-hour incubation time was chosen to allow the myogenic cells time to 
adhere to the gelatin while minimizing culture time in an attempt to possibly prevent the cells from 
differentiating any further because myogenic stem cells differentiate when they are cultured outside of 
their niche. After 12 hours, the fibroblasts had normal morphology and appeared adherent to the gelatin 
(Figure 9). 
 
Figure 9. Fibroblasts have normal morphology after one day of culture on gelatin vehicle. Fibroblasts were 
cultured on the gelatin vehicle to evaluate cytotoxicity. After 24 hours, the cells had normal morphology and they 
appeared to have adhered to the vehicle. 
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Myogenic Cell Transplantation 
 
To test the hypothesis that myogenic cell transplantation increases collateral capillary 
arterialization we used confocal microscopy (Figure 10) to count and measure the diameter of collateral 
capillaries and ACCs between ischemic and perfused arteriolar trees.  
 
Figure 10. Confocal images of arterialized collateral capillary region. Confocal images were taken of ACCs 
between the ligated arteriolar tree and an adjacent arteriolar tree using a 20x objective. (A,D) Alpha-smooth muscle 
actin positive vessels show arterioles and ACCs. (B,E) Lectin positive vessels include both capillaries and ACCs. 
(C,F) Composite images combining A and B or D and E.  A-C are images of an operated muscle and D-F are images 
of a sham muscle. Scale bars are 50µm. 
 
There was no difference in the total number of vessels between treatment groups (12.4 ± 0.6 
vessels with thrombin, 13.6 ± 0.5 vessels with myogenic cells, 12.5 ± 0.3 with vehicle, 13.7 ± 0.6 vessels 
with ligation only, and 13.6 ± 0.3 vessels in sham muscles) (Figure 11). To determine if myogenic cell 
transplantation increases ACC number, we counted alpha-smooth muscle actin positive vessels. 
Thrombin, which enhances collateral capillary arteriogenesis [75], increased the ACC number (9.3 ± 0.5 
vessels versus 7.1 ± 0.4 vessels with myogenic cells, 6.6 ± 0.1 vessels with vehicle, and 7.5 ± 0.3 vessels 
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with ligation only) (Figure 11). There was limited variation in ACC number between imaging regions, 
which suggests that 3 regions were sufficient for imaging. 
 
 
Figure 11. Thrombin increases number of arterialized collateral capillaries. Capillaries and ACCs were counted 
between ischemic and perfused trees in myogenic cells (n=6), vehicle (n=6), thrombin (n=5), ligation only (n=5), 
and sham (n=24) replicates replicates at day 7 using a 20x objective on a confocal microscope. Thrombin increased 
the number of ACCs. There was no difference in the total number of vessels between groups. (*, p<0.05 for a-SMA 
positive vessels in thrombin treated versus all other groups) 
 
Previously, thrombin decreased the number of ACCs in the region with the largest collateral [75]. 
To determine if myogenic cells have a similar effect, ACCs were counted in the region of the muscle with 
the largest collateral. While the previous ACC numbers were determined by counting ACCs in regions 
with average diameter ACCs (Figure 11), these measurements were determined by finding each 
replicate’s largest ACC and counting the ACCs in that region. Both thrombin and myogenic cells 
decreased ACC number in this region (8.5 ± 1.2 vessels and 9.7 ± 1.2 vessels versus 14.8 ± 0.9 vessels 
with vehicle and 13.7 ± 0.9 vessels with ligation only) (Figure 12). 
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Figure 12. Thrombin decreases number of arterialized collateral capillaries in region with largest collateral. 
ACCs were counted between ischemic and perfused trees in mice without PECs in myogenic cells (n=4), vehicle 
(n=3), thrombin (n=3), and ligation only (n=3) replicates replicates at day 7 using a 20x objective on a confocal 
microscope. (A) Example image of a region of average diameter ACCs (B) Example image of ACCs in the region 
with the largest collateral. (C) Myogenic cells and thrombin decreased the number of ACCs in the region with the 
largest collateral. (*, p<0.05 vs vehicle and ligation only) 
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The decrease in vessel number suggests that myogenic cells could be affecting only selected 
collaterals, allowing them to enlarge slightly more than surrounding collaterals which increases the shear 
stress in that collateral and allows it to continue to enlarge faster than its neighbors. Therefore, to 
determine if myogenic cell transplantation increases overall ACC diameter, alpha-smooth muscle actin 
positive vessel diameters were measured. Myogenic cells increased ACC diameter (12.1 ± 0.8 µm and 
11.9 ± 0.5 µm) compared to the vehicle (10.1 ± 0.4 µm) and ligation only (10.5 ± 0.4 µm), but not 
compared to thrombin (11.9 ± 0.5 µm) (Figure 10). There was no difference in capillary size between the 
ligated and sham muscles or between treatment groups (Figure 13). There was also limited variation in 
ACC diameter between imaging regions, which suggests that 3 regions were sufficient for imaging. 
 
 
Figure 13. Myogenic cells increase arterialized collateral capillary size. Capillary and ACC diameters were 
measured between two arterial trees in myogenic cells (n=6), vehicle (n=6), thrombin (n=5), and ligation only (n=5) 
replicates replicates at day 7 using a 20x objective on a confocal microscope. Myogenic cells increased ACC 
diameter compared to vehicle and ligation only. There was no difference in capillary size between ligated and sham 
muscles or between treatment groups. (*, p<0.05 versus vehicle and ligation only) 
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Even though thrombin did not increase the average ACC diameter, previous work demonstrated 
that thrombin increases the maximum ACC diameter [75], so we determined if myogenic cells have a 
similar effect. Both myogenic cells and thrombin increased the maximum ACC diameter (29.9 ± 3.4 µm 
with myogenic cells and 27.9 ± 2.0 µm with thrombin versus 17.9 ± 1.7 µm with vehicle and 18.9 ± 1.1 
µm with ligation only) (Figure 14). 
 
Figure 14. Myogenic cells increase maximum arterialized collateral capillary diameter. The largest ACC 
diameter was measured in myogenic cells (n=4), vehicle (n=4), thrombin (n=3), and ligation only (n=3) replicates at 
day 7 using a 20x objective on a confocal microscope. Myogenic cells and thrombin replicates increased the 
maximum diameter ACC compared to the other two groups. (*, p<0.05 vs gelatin and ligation only) 
 
Some Balb/C mice have pre-existing collaterals (PECs), which may affect arteriogenesis because 
blood flows along the path of least resistance [76], and arteriogenesis occurs in response to increased 
shear stress due to increased blood flow. Therefore, it is possible that a PEC ‘steals’ flow and the majority 
of the remodeling happens in the PEC. To determine if PECs influenced the number of ACCs, mice were 
analyzed in two groups: mice with PECs (n = 2 for all groups) and mice without PECs (n = 4 for 
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myogenic cells and vehicle, n = 3 for thrombin and ligation only). In mice without PECs, thrombin 
increased the number of ACCs (9.9 ± 0.5 vessels versus 7.1 ± 0.5 vessels with myogenic cells, 6.5 ± 0.2 
vessels with vehicle, and 7.7 ± 0.1 vessels with ligation only) (Figure 15). There was no difference in the 
number ACCs between mice without PECs and mice with PECs for all groups (Figure 15). 
 
Figure 15. Thrombin increases number of arterialized collateral capillaries in mice without PECs. ACCs were 
counted between ischemic and perfused trees in myogenic cells (PEC: n=2, No PEC: n=4), vehicle (PEC: n=2, No 
PEC: n=4), thrombin (PEC: n=2, No PEC: n=3), and ligation only (PEC: n=2, No PEC: n=3) replicates at day 7 
using a 20x objective on a confocal microscope. There was no difference in the number of ACCs in mice with a 
PEC and mice without a PEC. In mice without a PEC, thrombin increased the number of ACCs. (*, p<0.05 versus 
all other groups) 
 
To determine if PECs influence ACC size, ACC diameters were compared in mice with PECs and 
in mice without PECs. Mice without PECs trended towards a larger ACC diameter than mice without 
PECs (Figure 16). Additionally, in mice without a PEC, myogenic cells increased ACC diameter 
compared to other treatment groups (13.7 ± 1.2 µm with myogenic cells, 10.5 ± 0.5 µm with vehicle, 13.4 
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± 0.6 µm with thrombin, and 12.0 ± 0.5 µm with ligation only), and thrombin increased diameter 
compared to vehicle (Figure 16).   
 
Figure 16. Myogenic cells increase arterialized collateral capillary diameter in mice without PECs. Capillary 
and ACC diameters were measured between two arterial trees in myogenic cells (PEC: n=2, No PEC: n=4), vehicle 
(PEC: n=2, No PEC: n=4), thrombin (PEC: n=2, No PEC: n=3), and ligation only (PEC: n=2, No PEC: n=3) 
replicates at day 7 using a 20x objective on a confocal microscope. There was a trend toward an increased ACC size 
in mice without a PEC. Myogenic cell transplantation increased ACC diameter. (#, p<0.05 versus vehicle, thrombin, 
and ligation only; *, p<0.05 versus vehicle) 
 
Because myogenic cells increase arteriogenesis and macrophages are an important contributor to 
arteriogenesis [77,78,79], we tested the hypothesis that myogenic cells increase ACC diameter by 
increasing macrophage recruitment. We used confocal microscopy to count the number of CD68 positive 
cells in the region in which ACCs form anastomoses between the ischemic and perfused arteriolar trees as 
well as to count the number of vessel associated CD68 cells (Figure 17).  
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Figure 17. Confocal images of CD68 positive cells. Confocal images were taken of CD68 positive cells between 
the ligated arteriolar tree and an adjacent arteriolar tree using a 20x objective. (A,D) Alpha-smooth muscle actin 
positive vessels show arterioles and ACCs. (B,E) CD68 positive cells indicate macrophages. (C,F) Composite 
images combining A and B or D and E.  A-C are images of an operated muscle and D-F are images of a sham 
muscle. Scale bar is 50µm. 
 
Ligation increased CD68 positive cells (Figure 18), but myogenic cells and thrombin did not 
enhance this effect (16.0 ± 0.5 cells with myogenic cells, 15.8 ± 0.4 cells with vehicle, 15.3 ± 0.5 with 
thrombin, and 15.5 ± 0.5 with ligation only) (Figure 18). Myogenic cells also did not affect the number of 
vessel associated cells (16.9 ± 0.8 cells with myogenic cells, 14.6 ± 0.7 cells with vehicle, 16.1 ± 0.7 with 
thrombin, and 17.1 ± 0.8 with ligation only) (Figure 18). There was limited variation in CD68 content 
between imaging regions, which suggests that 3 regions were sufficient for imaging. 
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Figure 18. Myogenic cell transplantation has no effect on CD68 cell count. CD68 
positive cells were counted between two arterial trees in myogenic cells (n=6), 
vehicle (n=6), thrombin (n=5), and ligation only (n=5) replicates replicates at day 7 
using a 20x objective on a confocal microscope. There was no difference in the 
number of CD68 cells between groups. (*, p < 0.05 vs sham)  
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 DISCUSSION 
 
Pre-existing collaterals improve the prognosis in patients with ischemic diseases, but some 
patients never develop angiographically-identifiable collateral vessels [3,4,5,8,9]. Additionally, females 
appear to have a worse prognosis than males for peripheral arterial occlusive disease (PAOD) [64,65,66], 
possibly due to impaired collateral development [70]. Collateral vessels develop through arteriogenesis in 
response to increased shear stress that triggers a cascade of events involving endothelial cell activation, 
macrophage recruitment, matrix degradation, and smooth muscle/endothelial cell proliferation. 
Arteriogenesis results in a collateral arteriole with an expanded diameter that helps restore blood flow to 
the ischemic area. Because current treatments for severe PAOD have limited positive outcomes [2], 
alternative treatments to promote arteriogenesis are needed. Cell transplantation is a promising treatment 
for PAOD, but there has been limited clinical success for multiple cell types including bone marrow 
mononuclear cells, bone marrow mesenchymal cells, and endothelial progenitor cells [29,30,39,40,44,45]. 
Tissue resident stem cells, such as myogenic stem cells, have not been investigated as a treatment for 
PAOD, but they have potential to promote arteriogenesis [46,51,55,56]. Therefore, we determined if 
arterialized collateral capillary (ACC) formation was impaired in female mice compared to male mice, 
developed a myogenic cell transplantation protocol, and tested the hypotheses that myogenic cell 
transplantation enhanced arteriogenesis and macrophage recruitment.  
Seven days post ligation, ACCs on the operated muscle were significantly larger in diameter than 
collateral capillaries in the sham muscle, demonstrating that outward remodeling occurred. There was 
also no difference in total number of vessels in the ligated and sham muscles, demonstrating that the 
ACCs developed through capillaries outwardly remodeling and recruiting smooth muscle cells, as 
observed previously [15,80]. Interestingly, there was no difference between males and females in ACC 
diameter or number. The lack of difference between male and female mice could have occurred because 
the mice used in this study were healthy, and clinical sex differences are observed in patients who are 
often elderly with comorbidities and other risk factors [65,66,67]. Unfortunately, we do not know of any 
arteriogenesis investigations in female mice with ischemic disease comorbidities, but arteriogenesis is 
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impaired in both aged and diabetic mice compared to healthy models [81,82], and female ApoE-/- mice 
exhibit endothelial dysfunction compared to male mice [83,84,85] and have larger atherosclerotic legions 
[86,87]. To determine if comorbidities affect arteriogenesis in female mice, a diabetic or aged mouse 
model could be investigated.    
Seven days post ligation, thrombin increased the number of ACCs compared to all other 
treatment groups, including myogenic cells. However, the increase in ACC number with thrombin 
treatment is not necessarily an advantage because it may not result in a more effective restoration of blood 
flow. In the mouse hindlimb ischemia model, the density of blood vessels in the hindlimb peaks seven 
days post ligation, and as the number of vessels decreased, the hindlimb perfusion stayed the same [88], 
suggesting that the increased number of vessels is not necessary to restore bloodflow. With other 
arteriogenic factors, such as Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor 
(VEGF), the initial response to treatment is accelerated [89,90,91], but at later timepoints, there was no 
difference in perfusion [92], and the excess vessels formed during the initial accelerated development 
appear to be leaky and therefore not functional [92] . Previous work has demonstrated that thrombin 
augments the remodeling process at early timepoints similar to FGF and VEGF [75,93]. The 
administration of thrombin may promote the growth of blood vessels that are unnecessary to restore shear 
stress in the collateral zone, and therefore will regress at a later timepoint. Although myogenic cells did 
not increase in the number of ACCs, increasing the number of ACCs may not be necessary for ischemic 
recovery. To determine if thrombin’s effect is temporary, a study with longer endpoints such as 14 or 28 
days could be performed. 
Even though myogenic cells had no effect on the number of ACCs, both myogenic cells and 
thrombin increased ACC diameter. The maximum ACC diameter was also larger with both thrombin and 
myogenic cells. Additionally, in the region of the muscle with the largest collateral, both treatments 
decreased the number of ACCs compared to the other two treatment groups. Previous work has 
demonstrated that thrombin augments the remodeling of only certain collaterals [75]. The results from 
this study suggest that myogenic cell transplantation has a similar effect to thrombin injections, which 
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supports our hypothesis that myogenic cells would augment arteriogenesis. Myogenic cells secrete factors 
such as matrix metalloproteinases (MMPs) and VEGF [94,95] which are involved in arteriogenesis 
signaling and could be secreting these factors to accelerate arteriogenesis. VEGF is responsible for 
endothelial cell proliferation during arteriogenesis [96,97,98], and MMPs are responsible for degrading 
the matrix during vessel remodeling [14]. In a future study, to determine if myogenic cells are increasing 
arteriogenesis by secreting arteriogenic factors, we could analyze conditioned media to determine what 
proteins the myoblasts are secreting. 
Myogenic cells are not the only factor that can affect arteriogenesis in certain collaterals, pre-
existing collaterals (PECs), which are present in some mice from the Balb/C strain, could also affect 
which collaterals experience arteriogenesis. To determine if PECs affect collateral capillary 
arterialization, mice with PECs were analyzed separately from mice without PECs. There was a trend 
towards smaller ACCs in mice with PECs. Blood flows along the path of least resistance [76], so after a 
ligation blood flow would be redirected mainly through the PEC since it is the lowest resistance vessel. 
Because the PEC has the largest increase in blood flow and therefore the largest increase in shear stress, 
the PEC would be the main arteriole to undergo remodeling. While mice with a PEC appeared to have a 
trend towards reduced collateral capillary arteriogenesis, they did experience some collateral capillary 
arteriogenesis. Because the PEC was smaller than the original feed artery, it is possible that it could not 
normalize shear stress on its own, so some of the capillaries could have experienced an increase in shear 
stress causing some collateral capillary arteriogenesis [15]. In mice with a PEC, the PEC could have been 
the main collateral and therefore could have experienced the majority of the remodeling. While PECs may 
have an effect on ACC formation, including mice with a PEC in the initial vessel count and vessel 
diameter analysis may not have affected the results because the same conclusions about the effects of 
myogenic cells were drawn when mice with a PEC were excluded. To determine if the PEC experiences 
the largest increase in blood flow following ligation, we could utilize an imaging technique that allows for 
blood flow quantification such as laser speckle flowmetry [99]. In future studies, more replicates would 
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be included to determine if there are any statistical differences between mice with PECs and mice without 
PECs.   
In addition to secreting arteriogenic factors, myoblasts also recruit white blood cells [52,53]. To 
determine if myogenic cell transplantation increased macrophage recruitment, the number of CD68 
positive cells were counted. As expected, ligation increased the number of macrophages in the region 
with ACCs. Following ligation, the increased shear stress in the collateral vessel activates the 
endothelium, causing it to secrete MCP-1 which activates monocytes, enhancing their adhesion to the 
endothelium [100]. Once activated, monocytes extravasate into the tissue and become macrophages [100].  
Without macrophage recruitment, there is minimal arteriogenesis [77,78,79], so it was expected that the 
ligated muscle would see an increase in macrophages. However, both myogenic cells and thrombin had 
no effect on macrophage recruitment. The lack of difference between the groups could have occurred 
because the seven day timepoint is too long after ligation to see macrophage number differences. 
Macrophages are recruited to the collateral site early in arteriogenesis, and the number of macrophages 
peaks three days after ligation and is significantly decreased by day 7 [100,101]. Additionally, in 
thrombin treated mice, at three days post ligation there is only a trend towards an increase in the number 
of macrophages when compared to a control injection [75]. This suggests that arteriogenic agents such as 
thrombin or myogenic cells may be able to increase macrophage recruitment. Therefore, there may have 
been a difference in the number of macrophages between groups at 3 days post ligation that was gone by 
the 7 day timepoint used in this study. In a future study, to determine if myogenic cells increase 
macrophage recruitment earlier than 7 days post ligation, a 3 day timepoint could be added.  
Another possible reason for the failure of myogenic cells to affect macrophage number is that 
there may be differences in the numbers of each type of macrophage. Macrophages exist on a spectrum 
that ranges from classically activated to alternatively activated [102]. Classically activated macrophages 
are also referred to as M1 macrophages and are pro-inflammatory, while alternatively activated 
macrophages are also referred to as M2 macrophages and are involved in tissue remodeling [102]. M2 
macrophages are the main contributor to arteriogenesis and the main type of macrophage at the collateral 
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site [103,104]. Because a general macrophage marker, CD68, was used in this study, the number of each 
type of macrophage could not be determined. It is possible that myogenic cells increased the number of 
M2 macrophages, but this increase could not be observed. To determine if there are more M2 
macrophages a stain like CD206 that is specific to M2 macrophages [73] could be used in addition to the 
CD68 stain. 
There were a few limitations to this study. The sample size was small both for comparing mice 
with PECs to mice without PECs, and for comparisons made with only mice without PECs. When 
comparing mice with PECs to mice without PECs, only general trends could be observed. In the future, to 
draw statistical conclusions about the effect of a PEC on ACCs, a sample size of 6 mice with a PEC 
would be needed to have a power of 0.8. In addition, 6 replicates would also be needed to have power of 
0.8 for comparisons between treatment groups that were made only in mice without PECs, such as the 
maximum collateral diameter and the number of ACCs in the region with the largest collateral. 
Since this study was the first cell transplantation study in the spinotrapezius performed in this lab, 
the protocol could still be optimized. It is possible that myogenic cells did not increase the number of 
ACCs like thrombin because the number of cells transplanted was not optimized. In this study, 9.3 x 103 
cells was chosen based on results from previous work done in the lab in the mouse hindlimb, which used 
more cells but had disorganized blood vessel growth [105,106], as well as the number of cells available at 
the time of surgery. This study was the first cell transplantation study performed in the spinotrapezius, so 
a cell dose response study may be necessary to determine the optimal number of cells and to determine if 
changing the number of cells affects the number of ACCs. To determine the optimal number of cells to 
transplant, we could perform a dose response study with 1,000 to 1 million cells based on previous cell 
transplantation studies [88,107,108]. 
The vehicle could also be optimized for future cell transplantation studies. Gelatin was chosen for 
this initial cell transplantation study because it is biocompatible, easy to prepare, and inexpensive [74]. 
However, there are some disadvantages to gelatin. Ideally, the gelatin vehicle would have a modulus close 
to the modulus of muscle so that the myogenic cells are in an environment similar to their native ECM 
 31 
[109], but because gelatin must be boiled, it is difficult to create gelatin vehicles with a consistent gelatin 
concentration and therefore a consistent modulus. We chose the concentration of gelatin and EDC for the 
vehicles based on literature that measured the gelatin modulus [110,111,112,113,114], but were unable to 
determine if the modulus of the final vehicle was close to that of muscle. Another disadvantage to the 
gelatin vehicles was the use of a biopsy punch to create appropriately sized vehicles. Thick gelatin 
vehicles were used because they worked with the biopsy punch and thinner gels did not, but thinner gels 
may have been more beneficial. Also, because the biopsy punch was used during surgery when the cells 
were already on the gelatin vehicles, it was difficult to obtain an accurate cell count. In future studies, 
extra punches could be prepared and stained with BBI or a myogenic stem cell marker to estimate the 
number of transplanted myogenic stem cells. Additionally, during the follow-up procedure, the punches 
could be explanted and stained with the same stains to determine how many myogenic stem cells 
remained in the vehicle. It is also possible that the biopsy punch and the use of the forceps to place the 
gelatin vehicles beneath the spinotrapezius damaged some of the cells, despite performing both steps 
gently. To determine if implanting the vehicle damaged the cells, we could simulate the vehicle 
implantation and then use a live/dead stain on the vehicle. However, a construct that requires less 
interaction with surgical instruments would be ideal. A solution to the problems encountered with gelatin 
is the use of a thermoreversible hydrogel, which can be engineered with a specific modulus 
[115,116,117], and the cells can be added to the exact injected volume of vehicle. Since the vehicle would 
be injected directly into the mouse, it can be designed such that the syringe minimally damages the cells 
during construct delivery [118]. Additionally, with the thermoreversible gel the cells would be dispersed 
throughout the gel rather than on the surface as they are with the gelatin. Since the cells would be 
throughout the gel, they may be more protected from damage during transplantation than they are with 
gelatin, but any secreted factors would have to diffuse through the gel to reach the muscle.  
Myogenic cells increased ACC diameter and maximum ACC diameter, and decreased the number 
of ACCs in the region surrounding the maximum diameter ACC. This supports the hypothesis that 
myogenic cell transplantation is a potential arteriogenesis-enhancing treatment for PAOD. However, 
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myogenic cells did not affect macrophage recruitment. The methods used in this study still need 
optimization to determine if myogenic cells affect macrophage recruitment at earlier time points or in 
specific populations. Additionally, we found no differences in arteriogenesis between males and females. 
In future studies, diseased animal models can be utilized to determine if impaired arteriogenesis is 
involved in the clinical sex differences seen with PAOD. 
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APPENDICES 
Appendix A: Surgery and Experimental Protocols 
Spinotrapezius Ligation Protocol 
 
  
Date _____________   Spinotrapezius Ligation  Initials____________   
 
Mouse Information  
DOB: ______________________  
Sex: _______________________  
Tag: _______________________  
Genotype/strain: _____________  
Cage: ______________________  
Weight: _____________________  
 
Materials  
Instruments  
____1. Standard Pattern Forceps (1)  
____2. Iris Scissors (1)  
____3. S&T(1)  
____4. 5/45 (1)  
____5. Dumont #7’s (1)  
____6. Microdissection scissors (1)  
____7. Castro Viejos (1)  
Pre-sterilize in autoclave  
____8. Cotton gauze (4)  
____9. Cotton swabs (4)  
____10. 6.0 silk suture (2x1 in)  
____11. 7-0 Prolene Suture 
____12. Surgical Drape  
Obtained in surgery suite  
____13. Petri dish w/ sterile saline  
____14. Gloves (non-sterile and sterile) 
____15. FST heat pad w/ rectal probe  
____16. Recovery bin and weigh boat  
____17. Depilatory cream  
____18. non-sterile cotton swabs  
____19. non-sterile cotton gauze  
____20. Isolation mask & cap  
____21. Analgesic (buprenorphine)  
 
Surgery Preparation  
____22. Spray surgery area with Nolvasan  
____23. Weigh animal in weight boat  
____24. Place animal in anesthesia box  
____25. Open the oxygen cylinder and set anesthesia- 
machine flow meter to ~3 l·min-1 
____26. Anesthetize animal w/ 5% isoflurane  
____27. Reduce flow rate to 0.5-1.0 l·min-1 and the 
isoflurane to 1-3%  
____28. Lay animal prone with nose in nose-cone  
____29. Remove hair on anterior dorsal aspect of the 
animal with clippers and depilatory cream.  
____30. Apply vetinary ointment to eyes to avoid drying 
during the procedure  
____31. Give animal subcutaneous injection of 
buprenorphine  
____32. Lay animal prone on heat pad (w/ 4x4 on top) w/ 
nose in nose-cone  
____33. Insert rectal probe and set thermo-controller to 
35°C  
____34. Adjust focus, lighting, and center mouse 
____35. Don isolation mask, cap, and scrubs 
____36. Open sterile surgical instrument pack  
____37. Open sterile pack and dump in surgical instrument 
field 
____38. Place sterile petri dish in sterile field and fill with 
sterile saline 
____39. Don sterile gloves  
____40. Place surgical drape on the animal and arrange the 
items in sterile field 
 
Surgery  
____41. Make 5mm incision parallel to spine at intersection 
of fat pad and muscle  
____42. Dissect skin overlying the spinotrapezius muscle  
____43. Search for lateral feed artery vein pair jumping 
from the underlying fat pad to the spinotrapezius 
____44. Blunt dissect fat pad to reveal arteriole-venule pair, 
using paparvrine as a vasodilator if necessary 
____45. Blunt dissect arteriole away from venule 
____46. Pass a separated strand from 6-0 silk suture below 
the arteriole and tie off 
____47. Repeat again about 1mm above previous ligature 
____48. Cut arteriole between the two ligatures with micro 
dissection scissors 
____49. Suture incision with 7-0 prolene suture  
____50. Repeat for contralateral side to perform sham, but 
do not tie off ligature  
 
Post-Surgical  
____51. Give the animal a subcutaneous injection of 
buprenorphine  
____52. Place the animal in the recovery bin, on a blue 
bench cover, above a heat pad and allow to 
recover 
____53. Turn the flow meter down to 0, turn off the 
isoflurane, and close the oxygen cylinder  
____54. Indicate surgery on cage card  
 
Notes 
_______________________________________________ 
_______________________________________________ 
_______________________________________________ 
_______________________________________________ 
_______________________________________________ 
_______________________________________________ 
_______________________________________________ 
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Sterile Gelatin Preparation Protocol 
 
  
Date: _______________               Sterile Gelatin Preparation    Initials: ___________             
Sterile Materials 
• 25ml Erlenmeyer flask 
• Rubber stopper + tubing 
• Rubber stopper 
• Spatula 
• Distilled H2O 
• Gelatin powder 
• 10mL syringe 
• Syringe filter 
• Pipettes 
• 50 mL conicals 
• 24 Well Plate 
 
Non-Sterile Materials 
• Hot plate 
• Analytical balance 
• 6mM 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) 
 
Procedure 
___1. Turn hot plate on to 200°C 
___2. In the hood, open the sterile packs with the Erlenmeyer flask and the rubber 
stopper 
___3. Weigh empty 25ml Erlenmeyer flask + rubber stopper on an analytical balance 
and zero the balance  
___4. Bring the Erlenmeyer flask back to the hood, and bring the gelatin into the hood 
___5. Open the sterile pack with the spatula and use to put some gelatin powder into the 
Erlenmeyer flask 
___6. Put the rubber stopper back on the flask and weigh it on the analytical balance 
___7. Add enough distilled H2O to the flask to make a 10% gelatin solution (by weight) 
___8. Open the sterile pack with the rubber stopper + tubing and put it on the flask  
___9. Bring the flask to the hot, wait for it to reach a boil, and then allow it to boil for 5 
minutes 
___10. Bring the flask back into the hood and put 0.3mL of the gelatin solution in each 
well 
___11. While the gelatin in solidifying use the syringe filters to filter the 6mM EDC  
___12. Once the gelatin has solidified, add 0.5mL of EDC to each well  
___13. Leave the gelatin in the EDC solution overnight at 4°C to allow for crosslinking 
___14. The next day aspirate the EDC solution and wash the gel 3x30 minutes with 
sterile H2O 
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Development of Gelatin Boiling Technique 
 
We tried a couple techniques for sealing and venting the gelatin solution before developing the 
final solution. The first attempt utilized a foam stopper in an Erlenmeyer flask, but this method did not 
allow sufficient ventilation. The pressure buildup in the flask prevented the foam stopper from sealing the 
flask throughout the entire boiling process. The second attempt was to use a side arm distilling head and a 
round bottom flask borrowed from the chemistry department, which successfully sealed the flask and 
allowed ventilation. However, during the glassware testing a simpler solution was developed, so we 
decided to continue with the simpler solution for the final protocol. This solution used an Erlenmeyer 
flask with a vented rubber stopper and a piece of curved tubing attached with a tubing connector (Figure 
19). 
 
Figure 19. Preparation of sterile gelatin vehicles. Sterile 
gelatin was prepared by weighing gelatin powder in a cell 
culture hood and adding sterile water to make a 10% 
gelatin solution. The solution was then boiled outside the 
hood while sealed and vented, as shown, and aliquoted into 
a 24-well plate to solidify. 
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Myoblast Passing Protocol 
 
  
Date:                          Primary Myoblast Expansion Protocol                      Initials: ________	  
 
Purpose: To expand primary mouse myoblasts from live Extensor Digitorum (EDL) muscle fibers 
 
Necessary Materials: 
• Growth Media (20% FBS in Base Media) 
• SB 203580 working solution (10 mmol) 
• bFGF working solution (1µg/ml in PBS) 
• Cell Dissociation Solution - EDTA (Fisher 13151014) 
• Trypsin/EDTA (0.05% Invitrogen 25300-062) 
• PBS (-/-, Ca+2, Mg+2) 
• ECM coated flask 
 
1. ___ Obtain an ~80% confluent culture vessel 
a. myoblasts will begin to differentiate and form myotubes as they approach confluency 
2. ___ Clean Phase Contrast Microscope with 70% v/v Isopropanol (IPA) 
3. ___ Image save pictures of the culture with a phase contrast microscope 
4. ___ Determine passage ratio to be used 
a. myoblasts should not be split at a ratio higher than 1:3 
5. ___ Choose passaging method based upon goals and culture conditions 
a. use Trypsin for: 
i. for better cell distribution, single cell suspension 
ii. for a confluent flask with low overall confluency (1:1 pass) 
b. use EDTA for: 
i. preservation of surface receptors (integrins) 
ii. selective passaging (more differentiated cells will more strongly adhere) 
Trypsin Passaging 
1. ___ Warm Trypsin and Growth Media in 37C H2O bath immediately before use 
2. ___ Aspirate media from culture vessel 
3. ___ Wash with PBS (-/-) and aspirate 
4. ___ Add warm trypsin 
a.  0.04 ml/cm2 surface (T12.5 - 0.5 ml, T75 - 3 ml) 
5. ___ Immediately place in incubator for ~2 min 
6. ___ Observe with phase contrast microscope 
a. cells should begin to ball up and become phase bright 
7. ___ Hit the flask repeatedly to dislodge weakly adherent cells 
8. ___ Observe under the phase contrast microscope to ensure detachment of all cells 
a. If cells are still attached, return them to the incubator for an additional min and repeat 
9. ___ Add the same volume of Growth Media as trypsin to stop enzymatic cleavage 
10. ___  Wash the surface of the culture vessel with the cell suspension 
11. ___ Label a 15 ml conical tube and transfer the cell suspension 
12. ___ Centrifuge at 300g for 5 min to create a cell pellet 
13. ___ Aspirate media from the conical 
a. be careful to avoid aspirating the pellet 
14. ___ Resuspend in the volume of growth media (+ factors) appropriate for the chosen passage ratio 
15. ___ Repeatedly pipette up and down to break of cell clumps 
16. ___ Rock the culture vessel repeatedly:  forward/back and left/right to evenly disperse the cells 
a. Even cell distribution can be checked under the phase contrast microscope 
17. ___ Place in incubator 
a. close the door gently to prevent uneven cell distribution 
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Perfusion Fixation Protocol 
 
  
Date ______________ Perfusion Fixation Initials____________ 
 
Mouse Information 
DOB: ___________________ 
Sex: ____________________  
Tag: ____________________ 
Genotype/strain: __________ 
Cage: ___________________ 
Weight(g): _________________ 
 
Materials 
Non-Sterilize Dissection Instruments 
____1. Forceps (1) 
____2. Fine forceps (2) 
____3. Bone scissors (1) 
____4. Curved Iris scissors (1) 
____5. Microdissection scissors (1) 
____6. Vascular clamp (1) 
____7. Castroviejos  
 
Obtained in surgery suite 
____8. Tape 
____9. 20 mL syringes (2) 
____10. 5 mL syringe (1) 
____11. Syringe pump 
____12. Petri-dish 
____13. Bench cover 
____14. Depilatory cream 
____15. Clippers 
____16. Veterinary ointment  
____17. Heating pad 
____18. Catheter 
____19. Non-sterile saline 
____20. Cotton swabs 
____21. Gauze sponges  
____22. Saran wrap 
 
Vasodilator Cocktail Preparation 
____23. Turn on water bath to 37ºC 
____24. 400 µL heparin  
____25. 1mL SNP(orange) 
____26. 600µL Adenosine(clear) 
____27. 38mL PBS solution 
____28. 5 mL 4% Paraformaldehyde (PFA) 
____29. Thaw SNP, Adenosine and PFA 
____30. Add heparin, SNP, Adenosine, and PBS 
solution together in a 50mL conical 
____31. Place vasodilator cocktail in water bath 
 
Procedure Preparation 
____32. Obtain saline filled petri-dish, cotton 
swab, and instruments  
 
Fixation 
____33. Remove hair on back by shaving & 
depilation  
____34. Expose muscles of interest and blunt 
dissect to aid in removal post-fixation, 
then cover with saran wrap 
____35. Tape animal in supine position to 4X4 
gauze sponge over heating pad 
____36. Fill 10mL syringe with 10 mL warm 
Vaso D, load into syringe pump and 
attach catheter 
____37. Flow liquid through the catheter to the 
tip to prevent air from being injected 
into circulatory system 
____38. Lift skin from muscle in abdominal 
region and cut a window over the 
sternum 
____39. Lift sternum and cut connective tissue 
under 
____40. Use bone scissors to quickly cut through 
the ribs to the armpit on both sides  
____41. Clamp sternum with castroviejos and 
reflect towards mouse’s head 
____42. Cut diaphragm with curved iris scissors 
to open chest cavity  
____43. Cut away excess tissue around the heart 
____44. Make a small incision in the apex of the 
heart 
____45. Insert catheter and clamp with vascular 
clamp and cut right atrium 
____46. Inject Vaso D solution into animal 
approximately 4x 10mL (2 mL/min, 
14.43 mm diameter), soaking up excess 
blood and fluids with gauze sponges  
____47. Inject 5 mL PFA (1 mL/min, 11.99 mm 
diameter) 
____48. Dissect out muscles of interest using fine 
forceps and microdissection scissors  
____49. Turn off water bath, cover scope, turn 
off oxygen, turn off isofluorane, and 
clean instruments 
 
Notes 
__________________________________________ 
__________________________________________ 
__________________________________________ 
__________________________________________ 
__________________________________________ 
__________________________________________ 
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Staining Protocol 
 
  
Date: _________      Alpha-Smooth Muscle Actin, Lectin, and CD68 Staining Protocol Initials:_______ 
 
Materials 
• 24-well culture plates (Cat#: 3738, Corning Incorporated) 
• PBS 
• 0.1% Triton-X (Cat#:T8787, Sigma-Aldrich) 
• 2% Bovine Serum Albumin (Cat# B6917, Sigma Aldrich) 
• Monoclonal Anti-Alpha Smooth Muscle Actin, Cy3 Conjugate (Cat#: C6198, Sigma-Aldrich) 
• Isolectin GS-IB4 from GRI DyLight 649 (Cat #: DL-1208, Vector Laboratories) 
• Rat Anti Mouse CD68 FA-11 Clone Alexa Fluor 488 (Cat #: MCA1957A488T, Bio-Rad) 
• Glass Slides 
• Glass Coverslips  
• Parafilm  
• Nail Polish 
• Aluminum foil 
 
Staining 
___1. Using forceps, remove muscle from PBS (stored in microcentrifuge tube at 4°C) and place in a 
single well of a 24-well culture plate. 
___2. Prepare antibody solution containing 1:200 1A4 clone (alpha-smooth muscle actin, Cy3 conjugate), 
1:100 Isolectin GS-IB4 from GRI (Alexa Fluor 647), and 1:200 Rat Anti Mouse CD68 FA-11 Clone 
(Alexa Fluor 488)   in 0.1% Triton-X, 2% BSA (reconstituted in PBS) in PBS, using 0.3mL of 
solution per muscle. 
___3. Wrap the 24-well plate in parafilm and incubate muscle in antibody solution at 4°C for 72 hours for 
the Spinotrapezius or 7 days for the Gracilis. 
___4. Wash in 0.1% Triton-x in PBS 3x for 20 minutes at room temperature. Cover plate with foil during 
each wash. 
___5. Wash in plain PBS for 30 minutes at room temperature. Cover with foil during wash. 
___6. Place 1-2 drops of 50/50 PBS and Glycerol onto slide.  
___7. Remove muscle from well using forceps and place on a slide. Depression slides are best for the 
gracilis because the muscle is thick and the coverslip will not lie flat on a flat slide. 
___8. Add 1-2 drops of 50/50 PBS and Glycerol to the top of the muscle and place coverslip over the 
muscle. 
___9. Paint edges of coverslip with clear nail polish to create a seal and prevent tissue desiccation. 
___10. Store slides at 4°C wrapped in foil or an opaque container between imaging. 
___11. Wait 24 hours before imaging to allow the glycerol to clear and the nail polish to dry. 
 
Imaging 
___12. Image between three arteriolar trees using the 20x objective on the confocal microscope.  
___13. Use the following lasers: Alexa Fluor 488 for CD68, Alexa Fluor 559 for alpha-smooth muscle 
actin, Alexa Fluor 647 for lectin 
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Appendix B: Sample Images 
Key 
Stain Color Meaning 
Red α-SMA vessels (ACCs) 
Blue Lectin vessels (capillaries) 
Green CD68 Cells (macrophages) 
 
Female Ligated 
 
Female Sham 
 
Male Ligated 
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Male Sham 
 
 
Myogenic Cells Ligated 
 
 
Myogenic Cells Sham 
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Vehicle Ligated  
 
 
Vehicle Sham 
 
 
Thrombin Ligated 
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Thrombin Sham 
 
 
Ligation Only Ligated 
 
 
Ligation Only Sham 
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Appendix C: Raw Data 
Male and Female Vessel Count Data 
Replicate Sex Muscle Region 
Total 
Vessels Capillaries 
α-SMA 
Vessels 
1 Male Ligated Region 1 PEC PEC PEC 
1 Male Ligated Region 2 PEC PEC PEC 
1 Male Ligated Region 3 PEC PEC PEC 
2 Male Ligated Region 1 9 4 5 
2 Male Ligated Region 2 10 6 4 
2 Male Ligated Region 3 10 4 5 
3 Male Ligated Region 1 12 7 5 
3 Male Ligated Region 2 10 5 5 
3 Male Ligated Region 3 8 3 5 
4 Male Ligated Region 1 11 6 5 
4 Male Ligated Region 2 11 7 4 
4 Male Ligated Region 3 10 6 4 
5 Male Ligated Region 1 17 12 5 
5 Male Ligated Region 2 17 12 5 
5 Male Ligated Region 3 15 10 5 
6 Male Ligated Region 1 13 8 5 
6 Male Ligated Region 2 13 8 5 
6 Male Ligated Region 3 14 9 5 
7 Male Ligated Region 1 10 4 6 
7 Male Ligated Region 2 10 5 5 
7 Male Ligated Region 3 9 3 6 
8 Male Ligated Region 1 PEC PEC PEC 
8 Male Ligated Region 2 PEC PEC PEC 
8 Male Ligated Region 3 PEC PEC PEC 
1 Male Sham Region 1 10 10 0 
1 Male Sham Region 2 12 12 0 
1 Male Sham Region 3 10 10 0 
2 Male Sham Region 1 10 10 0 
2 Male Sham Region 2 8 8 0 
2 Male Sham Region 3 10 10 0 
3 Male Sham Region 1 10 10 0 
3 Male Sham Region 2 10 10 0 
3 Male Sham Region 3 12 12 0 
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4 Male Sham Region 1 16 16 0 
4 Male Sham Region 2 9 9 0 
4 Male Sham Region 3 12 12 0 
5 Male Sham Region 1 12 12 0 
5 Male Sham Region 2 19 19 0 
5 Male Sham Region 3 14 14 0 
6 Male Sham Region 1 10 10 0 
6 Male Sham Region 2 15 15 0 
6 Male Sham Region 3 12 12 0 
7 Male Sham Region 1 16 16 0 
7 Male Sham Region 2 9 9 0 
7 Male Sham Region 3 11 11 0 
8 Male Sham Region 1 14 14 0 
8 Male Sham Region 2 11 11 0 
8 Male Sham Region 3 11 11 0 
1 Female Ligated Region 1 PEC PEC PEC 
1 Female Ligated Region 2 PEC PEC PEC 
1 Female Ligated Region 3 PEC PEC PEC 
2 Female Ligated Region 1 12 7 5 
2 Female Ligated Region 2 10 6 4 
2 Female Ligated Region 3 9 5 4 
3 Female Ligated Region 1 9 4 5 
3 Female Ligated Region 2 10 6 4 
3 Female Ligated Region 3 13 8 5 
4 Female Ligated Region 1 PEC PEC PEC 
4 Female Ligated Region 2 PEC PEC PEC 
4 Female Ligated Region 3 PEC PEC PEC 
5 Female Ligated Region 1 11 7 4 
5 Female Ligated Region 2 11 6 5 
5 Female Ligated Region 3 12 7 5 
6 Female Ligated Region 1 PEC PEC PEC 
6 Female Ligated Region 2 PEC PEC PEC 
6 Female Ligated Region 3 PEC PEC PEC 
7 Female Ligated Region 1 PEC PEC PEC 
7 Female Ligated Region 2 PEC PEC PEC 
7 Female Ligated Region 3 PEC PEC PEC 
8 Female Ligated Region 1 10 5 5 
8 Female Ligated Region 2 11 7 4 
8 Female Ligated Region 3 11 6 5 
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1 Female Sham Region 1 12 12 0 
1 Female Sham Region 2 9 9 0 
1 Female Sham Region 3 11 11 0 
2 Female Sham Region 1 10 10 0 
2 Female Sham Region 2 10 10 0 
2 Female Sham Region 3 11 11 0 
3 Female Sham Region 1 12 12 0 
3 Female Sham Region 2 11 11 0 
3 Female Sham Region 3     0 
4 Female Sham Region 1 11 11 0 
4 Female Sham Region 2 13 13 0 
4 Female Sham Region 3 14 14 0 
5 Female Sham Region 1 12 12 0 
5 Female Sham Region 2 11 11 0 
5 Female Sham Region 3 11 11 0 
6 Female Sham Region 1 11 11 0 
6 Female Sham Region 2 9 9 0 
6 Female Sham Region 3 12 12 0 
PEC indicates that the muscle had a pre-existing collateral and measurements were not taken 
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Male and Female Vessel Diameter Data 
Replicate Sex Muscle Region Vessel 
α–SMA Vessel 
Diameter (µm) 
Lectin Vessel 
Diameter (µm) 
1 Male Ligated Region 1 Vessel 1 PEC PEC 
1 Male Ligated Region 1 Vessel 2 PEC PEC 
1 Male Ligated Region 1 Vessel 3 PEC PEC 
1 Male Ligated Region 2 Vessel 1 PEC PEC 
1 Male Ligated Region 2 Vessel 2 PEC PEC 
1 Male Ligated Region 2 Vessel 3 PEC PEC 
1 Male Ligated Region 3 Vessel 1 PEC PEC 
1 Male Ligated Region 3 Vessel 2 PEC PEC 
1 Male Ligated Region 3 Vessel 3 PEC PEC 
2 Male Ligated Region 1 Vessel 1 12.5 6.1 
2 Male Ligated Region 1 Vessel 2 12.6 4.8 
2 Male Ligated Region 1 Vessel 3 10.2 4.4 
2 Male Ligated Region 2 Vessel 1 14.8   
2 Male Ligated Region 2 Vessel 2 12.0   
2 Male Ligated Region 2 Vessel 3 8.5   
2 Male Ligated Region 3 Vessel 1 12.1 4.6 
2 Male Ligated Region 3 Vessel 2 10.8 4.7 
2 Male Ligated Region 3 Vessel 3 10.9 4.0 
3 Male Ligated Region 1 Vessel 1 9.4 3.8 
3 Male Ligated Region 1 Vessel 2 7.5 3.9 
3 Male Ligated Region 1 Vessel 3 10.8 5.3 
3 Male Ligated Region 2 Vessel 1 9.7 4.7 
3 Male Ligated Region 2 Vessel 2 12.1 4.3 
3 Male Ligated Region 2 Vessel 3 12.4 4.1 
3 Male Ligated Region 3 Vessel 1 11.4 4.6 
3 Male Ligated Region 3 Vessel 2 9.8 4.5 
3 Male Ligated Region 3 Vessel 3 8.6 4.2 
4 Male Ligated Region 1 Vessel 1 11.8 4.4 
4 Male Ligated Region 1 Vessel 2 7.2 3.8 
4 Male Ligated Region 1 Vessel 3 11.1 4.1 
4 Male Ligated Region 2 Vessel 1 10.9 4.5 
4 Male Ligated Region 2 Vessel 2 10.6 3.1 
4 Male Ligated Region 2 Vessel 3 11.2 5.1 
4 Male Ligated Region 3 Vessel 1 11.2 5.4 
4 Male Ligated Region 3 Vessel 2 13.0 4.4 
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4 Male Ligated Region 3 Vessel 3 13.4 5.0 
5 Male Ligated Region 1 Vessel 1 11.6 4.5 
5 Male Ligated Region 1 Vessel 2 12.5 4.7 
5 Male Ligated Region 1 Vessel 3 6.9 4.5 
5 Male Ligated Region 2 Vessel 1 8.8 4.5 
5 Male Ligated Region 2 Vessel 2 8.6 4.8 
5 Male Ligated Region 2 Vessel 3 11.7 3.8 
5 Male Ligated Region 3 Vessel 1 15.3 4.1 
5 Male Ligated Region 3 Vessel 2 6.7 3.6 
5 Male Ligated Region 3 Vessel 3 12.5 4.8 
6 Male Ligated Region 1 Vessel 1 10.7 4.8 
6 Male Ligated Region 1 Vessel 2 14.0 5.0 
6 Male Ligated Region 1 Vessel 3 14.2 4.9 
6 Male Ligated Region 2 Vessel 1 10.9 3.7 
6 Male Ligated Region 2 Vessel 2 9.9 5.3 
6 Male Ligated Region 2 Vessel 3 10.6 3.9 
6 Male Ligated Region 3 Vessel 1 14.9 3.4 
6 Male Ligated Region 3 Vessel 2 11.0 4.0 
6 Male Ligated Region 3 Vessel 3 15.4 5.4 
7 Male Ligated Region 1 Vessel 1 12.3 4.4 
7 Male Ligated Region 1 Vessel 2 13.5 5.5 
7 Male Ligated Region 1 Vessel 3 11.4 4.5 
7 Male Ligated Region 2 Vessel 1 9.8 5.3 
7 Male Ligated Region 2 Vessel 2 9.4 5.7 
7 Male Ligated Region 2 Vessel 3 8.0 6.1 
7 Male Ligated Region 3 Vessel 1 11.1 5.0 
7 Male Ligated Region 3 Vessel 2 14.0 5.3 
7 Male Ligated Region 3 Vessel 3 13.9 4.4 
8 Male Ligated Region 1 Vessel 1 PEC PEC 
8 Male Ligated Region 1 Vessel 2 PEC PEC 
8 Male Ligated Region 1 Vessel 3 PEC PEC 
8 Male Ligated Region 2 Vessel 1 PEC PEC 
8 Male Ligated Region 2 Vessel 2 PEC PEC 
8 Male Ligated Region 2 Vessel 3 PEC PEC 
8 Male Ligated Region 3 Vessel 1 PEC PEC 
8 Male Ligated Region 3 Vessel 2 PEC PEC 
8 Male Ligated Region 3 Vessel 3 PEC PEC 
1 Male Sham Region 1 Vessel 1  N/A 5.3 
1 Male Sham Region 1 Vessel 2  N/A 5.2 
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1 Male Sham Region 1 Vessel 3  N/A 4.4 
1 Male Sham Region 2 Vessel 1  N/A 5.5 
1 Male Sham Region 2 Vessel 2  N/A 4.9 
1 Male Sham Region 2 Vessel 3  N/A 4.8 
1 Male Sham Region 3 Vessel 1  N/A 5.3 
1 Male Sham Region 3 Vessel 2  N/A 5.2 
1 Male Sham Region 3 Vessel 3  N/A 5.5 
2 Male Sham Region 1 Vessel 1  N/A 8.4 
2 Male Sham Region 1 Vessel 2  N/A 5.9 
2 Male Sham Region 1 Vessel 3  N/A 6.5 
2 Male Sham Region 2 Vessel 1  N/A 6.2 
2 Male Sham Region 2 Vessel 2  N/A 6.9 
2 Male Sham Region 2 Vessel 3  N/A 5.7 
2 Male Sham Region 3 Vessel 1  N/A 5.8 
2 Male Sham Region 3 Vessel 2  N/A 5.1 
2 Male Sham Region 3 Vessel 3  N/A 4.7 
3 Male Sham Region 1 Vessel 1  N/A 5.1 
3 Male Sham Region 1 Vessel 2  N/A 4.8 
3 Male Sham Region 1 Vessel 3  N/A 6.6 
3 Male Sham Region 2 Vessel 1  N/A 7.2 
3 Male Sham Region 2 Vessel 2  N/A 7.1 
3 Male Sham Region 2 Vessel 3  N/A 5.2 
3 Male Sham Region 3 Vessel 1  N/A 5.5 
3 Male Sham Region 3 Vessel 2  N/A 7.0 
3 Male Sham Region 3 Vessel 3  N/A 5.7 
4 Male Sham Region 1 Vessel 1  N/A 5.8 
4 Male Sham Region 1 Vessel 2  N/A 4.4 
4 Male Sham Region 1 Vessel 3  N/A 3.7 
4 Male Sham Region 2 Vessel 1  N/A 3.8 
4 Male Sham Region 2 Vessel 2  N/A 4.1 
4 Male Sham Region 2 Vessel 3  N/A 3.1 
4 Male Sham Region 3 Vessel 1  N/A 6.0 
4 Male Sham Region 3 Vessel 2  N/A 5.1 
4 Male Sham Region 3 Vessel 3  N/A 5.4 
5 Male Sham Region 1 Vessel 1  N/A 4.8 
5 Male Sham Region 1 Vessel 2  N/A 4.0 
5 Male Sham Region 1 Vessel 3  N/A 5.8 
5 Male Sham Region 2 Vessel 1  N/A 5.8 
5 Male Sham Region 2 Vessel 2  N/A 4.7 
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5 Male Sham Region 2 Vessel 3  N/A 6.9 
5 Male Sham Region 3 Vessel 1  N/A 7.4 
5 Male Sham Region 3 Vessel 2  N/A 6.6 
5 Male Sham Region 3 Vessel 3  N/A 7.6 
6 Male Sham Region 1 Vessel 1  N/A 4.3 
6 Male Sham Region 1 Vessel 2  N/A 5.5 
6 Male Sham Region 1 Vessel 3  N/A 6.2 
6 Male Sham Region 2 Vessel 1  N/A 6.4 
6 Male Sham Region 2 Vessel 2  N/A 4.4 
6 Male Sham Region 2 Vessel 3  N/A 6.8 
6 Male Sham Region 3 Vessel 1  N/A 6.2 
6 Male Sham Region 3 Vessel 2  N/A 5.4 
6 Male Sham Region 3 Vessel 3  N/A 5.0 
7 Male Sham Region 1 Vessel 1  N/A 4.7 
7 Male Sham Region 1 Vessel 2  N/A 4.4 
7 Male Sham Region 1 Vessel 3  N/A 4.7 
7 Male Sham Region 2 Vessel 1  N/A 5.1 
7 Male Sham Region 2 Vessel 2  N/A 3.6 
7 Male Sham Region 2 Vessel 3  N/A 4.3 
7 Male Sham Region 3 Vessel 1  N/A 4.4 
7 Male Sham Region 3 Vessel 2  N/A 5.0 
7 Male Sham Region 3 Vessel 3  N/A 5.3 
8 Male Sham Region 1 Vessel 1  N/A 4.9 
8 Male Sham Region 1 Vessel 2  N/A 4.0 
8 Male Sham Region 1 Vessel 3  N/A 4.7 
8 Male Sham Region 2 Vessel 1  N/A 4.5 
8 Male Sham Region 2 Vessel 2  N/A 4.1 
8 Male Sham Region 2 Vessel 3  N/A 3.7 
8 Male Sham Region 3 Vessel 1  N/A 4.6 
8 Male Sham Region 3 Vessel 2  N/A 4.1 
8 Male Sham Region 3 Vessel 3  N/A 5.0 
1 Female Ligated Region 1 Vessel 1 PEC PEC 
1 Female Ligated Region 1 Vessel 2 PEC PEC 
1 Female Ligated Region 1 Vessel 3 PEC PEC 
1 Female Ligated Region 2 Vessel 1 PEC PEC 
1 Female Ligated Region 2 Vessel 2 PEC PEC 
1 Female Ligated Region 2 Vessel 3 PEC PEC 
1 Female Ligated Region 3 Vessel 1 PEC PEC 
1 Female Ligated Region 3 Vessel 2 PEC PEC 
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1 Female Ligated Region 3 Vessel 3 PEC PEC 
2 Female Ligated Region 1 Vessel 1 9.9 3.3 
2 Female Ligated Region 1 Vessel 2 11.2 3.4 
2 Female Ligated Region 1 Vessel 3 12.4 4.1 
2 Female Ligated Region 2 Vessel 1 7.7 4.2 
2 Female Ligated Region 2 Vessel 2 7.3 5.2 
2 Female Ligated Region 2 Vessel 3 11.8 5.1 
2 Female Ligated Region 3 Vessel 1 7.8 5.8 
2 Female Ligated Region 3 Vessel 2 9.2 5.7 
2 Female Ligated Region 3 Vessel 3 10.1 4.7 
3 Female Ligated Region 1 Vessel 1 9.6 5.0 
3 Female Ligated Region 1 Vessel 2 12.3 4.3 
3 Female Ligated Region 1 Vessel 3 13.2 6.2 
3 Female Ligated Region 2 Vessel 1 12.1 7.5 
3 Female Ligated Region 2 Vessel 2 11.0 5.9 
3 Female Ligated Region 2 Vessel 3 8.3 5.7 
3 Female Ligated Region 3 Vessel 1 10.9 5.5 
3 Female Ligated Region 3 Vessel 2 13.5 6.0 
3 Female Ligated Region 3 Vessel 3 11.8 4.3 
4 Female Ligated Region 1 Vessel 1 PEC PEC 
4 Female Ligated Region 1 Vessel 2 PEC PEC 
4 Female Ligated Region 1 Vessel 3 PEC PEC 
4 Female Ligated Region 2 Vessel 1 PEC PEC 
4 Female Ligated Region 2 Vessel 2 PEC PEC 
4 Female Ligated Region 2 Vessel 3 PEC PEC 
4 Female Ligated Region 3 Vessel 1 PEC PEC 
4 Female Ligated Region 3 Vessel 2 PEC PEC 
4 Female Ligated Region 3 Vessel 3 PEC PEC 
5 Female Ligated Region 1 Vessel 1 19.3 4.9 
5 Female Ligated Region 1 Vessel 2 16.3 4.5 
5 Female Ligated Region 1 Vessel 3 8.3 3.6 
5 Female Ligated Region 2 Vessel 1 10.4 3.8 
5 Female Ligated Region 2 Vessel 2 7.6 4.2 
5 Female Ligated Region 2 Vessel 3 10.1 4.9 
5 Female Ligated Region 3 Vessel 1 9.8 3.4 
5 Female Ligated Region 3 Vessel 2 10.9 3.3 
5 Female Ligated Region 3 Vessel 3 8.6 3.0 
6 Female Ligated Region 1 Vessel 1 PEC PEC 
6 Female Ligated Region 1 Vessel 2 PEC PEC 
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6 Female Ligated Region 1 Vessel 3 PEC PEC 
6 Female Ligated Region 2 Vessel 1 PEC PEC 
6 Female Ligated Region 2 Vessel 2 PEC PEC 
6 Female Ligated Region 2 Vessel 3 PEC PEC 
6 Female Ligated Region 3 Vessel 1 PEC PEC 
6 Female Ligated Region 3 Vessel 2 PEC PEC 
6 Female Ligated Region 3 Vessel 3 PEC PEC 
7 Female Ligated Region 1 Vessel 1 PEC PEC 
7 Female Ligated Region 1 Vessel 2 PEC PEC 
7 Female Ligated Region 1 Vessel 3 PEC PEC 
7 Female Ligated Region 2 Vessel 1 PEC PEC 
7 Female Ligated Region 2 Vessel 2 PEC PEC 
7 Female Ligated Region 2 Vessel 3 PEC PEC 
7 Female Ligated Region 3 Vessel 1 PEC PEC 
7 Female Ligated Region 3 Vessel 2 PEC PEC 
7 Female Ligated Region 3 Vessel 3 PEC PEC 
8 Female Ligated Region 1 Vessel 1 13.5 4.5 
8 Female Ligated Region 1 Vessel 2 12.8 4.6 
8 Female Ligated Region 1 Vessel 3 12.7 4.3 
8 Female Ligated Region 2 Vessel 1 12.8 4.8 
8 Female Ligated Region 2 Vessel 2 8.6 4.1 
8 Female Ligated Region 2 Vessel 3 12.0 5.3 
8 Female Ligated Region 3 Vessel 1 9.6 4.7 
8 Female Ligated Region 3 Vessel 2 6.6 5.6 
8 Female Ligated Region 3 Vessel 3 6.4 5.1 
1 Female Sham Region 1 Vessel 1  N/A 5.0 
1 Female Sham Region 1 Vessel 2  N/A 4.5 
1 Female Sham Region 1 Vessel 3  N/A 4.7 
1 Female Sham Region 2 Vessel 1  N/A 6.4 
1 Female Sham Region 2 Vessel 2  N/A 4.3 
1 Female Sham Region 2 Vessel 3  N/A 6.1 
1 Female Sham Region 3 Vessel 1  N/A 5.0 
1 Female Sham Region 3 Vessel 2  N/A 5.2 
1 Female Sham Region 3 Vessel 3  N/A 5.2 
2 Female Sham Region 1 Vessel 1  N/A 4.4 
2 Female Sham Region 1 Vessel 2  N/A 5.2 
2 Female Sham Region 1 Vessel 3  N/A 5.8 
2 Female Sham Region 2 Vessel 1  N/A 5.8 
2 Female Sham Region 2 Vessel 2  N/A 6.9 
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2 Female Sham Region 2 Vessel 3  N/A 4.6 
2 Female Sham Region 3 Vessel 1  N/A 6.0 
2 Female Sham Region 3 Vessel 2  N/A 5.2 
2 Female Sham Region 3 Vessel 3  N/A 5.5 
3 Female Sham Region 1 Vessel 1  N/A 4.2 
3 Female Sham Region 1 Vessel 2  N/A 3.4 
3 Female Sham Region 1 Vessel 3  N/A 4.5 
3 Female Sham Region 2 Vessel 1  N/A 4.5 
3 Female Sham Region 2 Vessel 2  N/A 6.4 
3 Female Sham Region 2 Vessel 3  N/A 5.2 
4 Female Sham Region 1 Vessel 1  N/A 5.7 
4 Female Sham Region 1 Vessel 2  N/A 5.6 
4 Female Sham Region 1 Vessel 3  N/A 5.5 
4 Female Sham Region 2 Vessel 1  N/A 4.7 
4 Female Sham Region 2 Vessel 2  N/A 6.7 
4 Female Sham Region 2 Vessel 3  N/A 6.1 
4 Female Sham Region 3 Vessel 1  N/A 4.4 
4 Female Sham Region 3 Vessel 2  N/A 4.5 
4 Female Sham Region 3 Vessel 3  N/A 5.5 
5 Female Sham Region 1 Vessel 1  N/A 4.5 
5 Female Sham Region 1 Vessel 2  N/A 5.5 
5 Female Sham Region 1 Vessel 3  N/A 5.0 
5 Female Sham Region 2 Vessel 1  N/A 5.3 
5 Female Sham Region 2 Vessel 2  N/A 5.4 
5 Female Sham Region 2 Vessel 3  N/A 4.6 
5 Female Sham Region 3 Vessel 1  N/A 7.0 
5 Female Sham Region 3 Vessel 2  N/A 5.7 
5 Female Sham Region 3 Vessel 3  N/A 6.3 
6 Female Sham Region 1 Vessel 1  N/A 5.1 
6 Female Sham Region 1 Vessel 2  N/A 4.9 
6 Female Sham Region 1 Vessel 3  N/A 5.3 
6 Female Sham Region 2 Vessel 1  N/A 4.8 
6 Female Sham Region 2 Vessel 2  N/A 4.7 
6 Female Sham Region 2 Vessel 3  N/A 5.2 
6 Female Sham Region 3 Vessel 1  N/A 4.9 
6 Female Sham Region 3 Vessel 2  N/A 4.2 
6 Female Sham Region 3 Vessel 3  N/A 4.6 
PEC indicates that the muscle had a pre-existing collateral and measurements were not taken 
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Cell Transplantation Vessel Count Data 
Replicate Treatment 
PEC or 
No PEC Muscle Region 
Total 
Vessels Capillaries 
α-SMA 
Vessels 
1 Myogenic Cells PEC Ligated Region 1 15 7 8 
1 Myogenic Cells PEC Ligated Region 2 15 7 8 
1 Myogenic Cells PEC Ligated Region 3 15 8 7 
2 Myogenic Cells No PEC Ligated Region 1 13 7 6 
2 Myogenic Cells No PEC Ligated Region 2 9 6 3 
2 Myogenic Cells No PEC Ligated Region 3 14 9 5 
3 Myogenic Cells PEC Ligated Region 1 15 8 7 
3 Myogenic Cells PEC Ligated Region 2 16 10 6 
3 Myogenic Cells PEC Ligated Region 3 15 8 7 
4 Myogenic Cells No PEC Ligated Region 1 15 7 8 
4 Myogenic Cells No PEC Ligated Region 2 14 5 9 
4 Myogenic Cells No PEC Ligated Region 3 11 2 9 
5 Myogenic Cells No PEC Ligated Region 1 8 0 8 
5 Myogenic Cells No PEC Ligated Region 2 13 6 7 
5 Myogenic Cells No PEC Ligated Region 3 14 5 9 
6 Myogenic Cells No PEC Ligated Region 1 14 7 7 
6 Myogenic Cells No PEC Ligated Region 2 15 8 7 
6 Myogenic Cells No PEC Ligated Region 3 14 7 7 
1 Vehicle PEC Ligated Region 1 12 6 6 
1 Vehicle PEC Ligated Region 2 14 7 7 
1 Vehicle PEC Ligated Region 3 13 6 7 
2 Vehicle PEC Ligated Region 1 13 6 7 
2 Vehicle PEC Ligated Region 2 13 6 7 
2 Vehicle PEC Ligated Region 3 12 5 7 
3 Vehicle No PEC Ligated Region 1 11 5 6 
3 Vehicle No PEC Ligated Region 2 13 6 7 
3 Vehicle No PEC Ligated Region 3 10 5 5 
4 Vehicle No PEC Ligated Region 1 11 11   
4 Vehicle No PEC Ligated Region 2 11 4 7 
4 Vehicle No PEC Ligated Region 3 15 8 7 
5 Vehicle No PEC Ligated Region 1 13 6 7 
5 Vehicle No PEC Ligated Region 2 12 5 7 
5 Vehicle No PEC Ligated Region 3 13 7 6 
6 Vehicle No PEC Ligated Region 1 13 6 7 
6 Vehicle No PEC Ligated Region 2 13 7 6 
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6 Vehicle No PEC Ligated Region 3 13 6 7 
1 Thrombin No PEC Ligated Region 1 14 4 10 
1 Thrombin No PEC Ligated Region 2 14 5 9 
1 Thrombin No PEC Ligated Region 3 15 7 8 
2 Thrombin PEC Ligated Region 1 13 2 11 
2 Thrombin PEC Ligated Region 2 8 -3 11 
2 Thrombin PEC Ligated Region 3 14 4 10 
3 Thrombin No PEC Ligated Region 1 14 4 10 
3 Thrombin No PEC Ligated Region 2 14 3 11 
3 Thrombin No PEC Ligated Region 3 12 4 8 
4 Thrombin No PEC Ligated Region 1 11 0 11 
4 Thrombin No PEC Ligated Region 2 14 2 12 
4 Thrombin No PEC Ligated Region 3 11 1 10 
5 Thrombin PEC Ligated Region 1 12 7 5 
5 Thrombin PEC Ligated Region 2 12 5 7 
5 Thrombin PEC Ligated Region 3 8 2 6 
1 Ligation Only PEC Ligated Region 1 13 6 7 
1 Ligation Only PEC Ligated Region 2 12 5 7 
1 Ligation Only PEC Ligated Region 3 15 6 9 
2 Ligation Only No PEC Ligated Region 1 13 3 10 
2 Ligation Only No PEC Ligated Region 2 11 3 8 
2 Ligation Only No PEC Ligated Region 3 16 6 10 
3 Ligation Only No PEC Ligated Region 1 16 10 6 
3 Ligation Only No PEC Ligated Region 2 12 5 7 
3 Ligation Only No PEC Ligated Region 3 12 4 8 
4 Ligation Only No PEC Ligated Region 1 12 5 7 
4 Ligation Only No PEC Ligated Region 2 13 7 6 
4 Ligation Only No PEC Ligated Region 3 11 4 7 
5 Ligation Only PEC Ligated Region 1 18 10 8 
5 Ligation Only PEC Ligated Region 2 16 10 6 
5 Ligation Only PEC Ligated Region 3 15 8 7 
1 Myogenic Cells PEC Sham Region 1 14 14 0 
1 Myogenic Cells PEC Sham Region 2 14 14 0 
1 Myogenic Cells PEC Sham Region 3 14 14 0 
2 Myogenic Cells No PEC Sham Region 1 10 10 0 
2 Myogenic Cells No PEC Sham Region 2 15 15 0 
2 Myogenic Cells No PEC Sham Region 3 12 12 0 
3 Myogenic Cells PEC Sham Region 1 17 17 0 
3 Myogenic Cells PEC Sham Region 2 15 15 0 
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3 Myogenic Cells PEC Sham Region 3 13 13 0 
4 Myogenic Cells No PEC Sham Region 1 16 16 0 
4 Myogenic Cells No PEC Sham Region 2 19 19 0 
4 Myogenic Cells No PEC Sham Region 3 18 18 0 
5 Myogenic Cells No PEC Sham Region 1 16 16 0 
5 Myogenic Cells No PEC Sham Region 2 14 14 0 
5 Myogenic Cells No PEC Sham Region 3 16 16 0 
6 Myogenic Cells No PEC Sham Region 1 13 13 0 
6 Myogenic Cells No PEC Sham Region 2 13 13 0 
6 Myogenic Cells No PEC Sham Region 3 15 15 0 
1 Vehicle PEC Sham Region 1 11 11 0 
1 Vehicle PEC Sham Region 2 15 15 0 
1 Vehicle PEC Sham Region 3 17 17 0 
2 Vehicle PEC Sham Region 1 12 12 0 
2 Vehicle PEC Sham Region 2 14 14 0 
2 Vehicle PEC Sham Region 3 12 12 0 
3 Vehicle No PEC Sham Region 1 8 8 0 
3 Vehicle No PEC Sham Region 2 11 11 0 
3 Vehicle No PEC Sham Region 3 8 8 0 
4 Vehicle No PEC Sham Region 1 10 10 0 
4 Vehicle No PEC Sham Region 2 12 12 0 
4 Vehicle No PEC Sham Region 3 12 12 0 
5 Vehicle No PEC Sham Region 1 15 15 0 
5 Vehicle No PEC Sham Region 2 13 13 0 
5 Vehicle No PEC Sham Region 3 13 13 0 
6 Vehicle No PEC Sham Region 1 17 17 0 
6 Vehicle No PEC Sham Region 2 15 15 0 
6 Vehicle No PEC Sham Region 3 14 14 0 
1 Thrombin No PEC Sham Region 1 14 14 0 
1 Thrombin No PEC Sham Region 2 12 12 0 
1 Thrombin No PEC Sham Region 3 11 11 0 
2 Thrombin PEC Sham Region 1 14 14 0 
2 Thrombin PEC Sham Region 2 10 10 0 
2 Thrombin PEC Sham Region 3 10 10 0 
3 Thrombin No PEC Sham Region 1 12 12 0 
3 Thrombin No PEC Sham Region 2 14 14 0 
3 Thrombin No PEC Sham Region 3 14 14 0 
4 Thrombin No PEC Sham Region 1 12 12 0 
4 Thrombin No PEC Sham Region 2 14 14 0 
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4 Thrombin No PEC Sham Region 3 16 16 0 
5 Thrombin PEC Sham Region 1 19 19 0 
5 Thrombin PEC Sham Region 2 16 16 0 
5 Thrombin PEC Sham Region 3 15 15 0 
1 Ligation Only PEC Sham Region 1 10 10 0 
1 Ligation Only PEC Sham Region 2 12 12 0 
1 Ligation Only PEC Sham Region 3 16 16 0 
2 Ligation Only No PEC Sham Region 1 12 12 0 
2 Ligation Only No PEC Sham Region 2 14 14 0 
2 Ligation Only No PEC Sham Region 3 11 11 0 
3 Ligation Only No PEC Sham Region 1 15 15 0 
3 Ligation Only No PEC Sham Region 2 16 16 0 
3 Ligation Only No PEC Sham Region 3 13 13 0 
4 Ligation Only No PEC Sham Region 1 13 13 0 
4 Ligation Only No PEC Sham Region 2 14 14 0 
4 Ligation Only No PEC Sham Region 3 18 18 0 
5 Ligation Only PEC Sham Region 1 13 13 0 
5 Ligation Only PEC Sham Region 2 14 14 0 
5 Ligation Only PEC Sham Region 3 14 14 0 
 
  
 65 
Cell Transplantation Vessel Diameter Data 
Replicate Treatment 
PEC or 
No PEC Muscle Region Vessel 
α-SMA 
Vessel 
Diameter 
(µm) 
Lectin 
Vessel 
Diameter 
(µm) 
1 Myogenic Cells PEC Ligated Region 1 Vessel 1 9.0 5.0 
1 Myogenic Cells PEC Ligated Region 1 Vessel 2 8.6 4.2 
1 Myogenic Cells PEC Ligated Region 1 Vessel 3 7.7 5.7 
1 Myogenic Cells PEC Ligated Region 2 Vessel 1 10.6 4.1 
1 Myogenic Cells PEC Ligated Region 2 Vessel 2 8.0 3.5 
1 Myogenic Cells PEC Ligated Region 2 Vessel 3 12.3 5.1 
1 Myogenic Cells PEC Ligated Region 3 Vessel 1 7.9 6.2 
1 Myogenic Cells PEC Ligated Region 3 Vessel 2 9.2 4.4 
1 Myogenic Cells PEC Ligated Region 3 Vessel 3 8.1 3.7 
2 Myogenic Cells No PEC Ligated Region 1 Vessel 1 16.0 5.7 
2 Myogenic Cells No PEC Ligated Region 1 Vessel 2 18.9 5.3 
2 Myogenic Cells No PEC Ligated Region 1 Vessel 3 18.7 5.4 
2 Myogenic Cells No PEC Ligated Region 2 Vessel 1 28.2 4.9 
2 Myogenic Cells No PEC Ligated Region 2 Vessel 2 26.3 5.3 
2 Myogenic Cells No PEC Ligated Region 2 Vessel 3 43.4 4.9 
2 Myogenic Cells No PEC Ligated Region 3 Vessel 1 10.7 8.0 
2 Myogenic Cells No PEC Ligated Region 3 Vessel 2 15.8 6.9 
2 Myogenic Cells No PEC Ligated Region 3 Vessel 3 12.9 7.4 
3 Myogenic Cells PEC Ligated Region 1 Vessel 1 10.1 6.6 
3 Myogenic Cells PEC Ligated Region 1 Vessel 2 10.3 5.8 
3 Myogenic Cells PEC Ligated Region 1 Vessel 3 7.7 6.0 
3 Myogenic Cells PEC Ligated Region 2 Vessel 1 12.4 8.7 
3 Myogenic Cells PEC Ligated Region 2 Vessel 2 9.9 7.5 
3 Myogenic Cells PEC Ligated Region 2 Vessel 3 11.9 8.6 
3 Myogenic Cells PEC Ligated Region 3 Vessel 1 14.0 6.6 
3 Myogenic Cells PEC Ligated Region 3 Vessel 2 13.7 4.9 
3 Myogenic Cells PEC Ligated Region 3 Vessel 3 10.4 6.4 
4 Myogenic Cells No PEC Ligated Region 1 Vessel 1 11.5 4.7 
4 Myogenic Cells No PEC Ligated Region 1 Vessel 2 8.4 4.1 
4 Myogenic Cells No PEC Ligated Region 1 Vessel 3 8.9 4.1 
4 Myogenic Cells No PEC Ligated Region 2 Vessel 1 9.0 4.8 
4 Myogenic Cells No PEC Ligated Region 2 Vessel 2 8.1 5.3 
4 Myogenic Cells No PEC Ligated Region 2 Vessel 3 9.1 5.0 
4 Myogenic Cells No PEC Ligated Region 3 Vessel 1 10.5 4.4 
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4 Myogenic Cells No PEC Ligated Region 3 Vessel 2 8.3 3.9 
4 Myogenic Cells No PEC Ligated Region 3 Vessel 3 10.7 3.6 
5 Myogenic Cells No PEC Ligated Region 1 Vessel 1 12.2 4.8 
5 Myogenic Cells No PEC Ligated Region 1 Vessel 2 14.5 5.6 
5 Myogenic Cells No PEC Ligated Region 1 Vessel 3 13.9 4.7 
5 Myogenic Cells No PEC Ligated Region 2 Vessel 1 19.9 4.7 
5 Myogenic Cells No PEC Ligated Region 2 Vessel 2 20.5 4.7 
5 Myogenic Cells No PEC Ligated Region 2 Vessel 3 20.7 5.1 
5 Myogenic Cells No PEC Ligated Region 3 Vessel 1 10.4 3.6 
5 Myogenic Cells No PEC Ligated Region 3 Vessel 2 10.9 4.0 
5 Myogenic Cells No PEC Ligated Region 3 Vessel 3 10.4 3.9 
6 Myogenic Cells No PEC Ligated Region 1 Vessel 1 18.9 4.9 
6 Myogenic Cells No PEC Ligated Region 1 Vessel 2 16.2 4.1 
6 Myogenic Cells No PEC Ligated Region 1 Vessel 3 17.9 5.8 
6 Myogenic Cells No PEC Ligated Region 2 Vessel 1 11.3 5.2 
6 Myogenic Cells No PEC Ligated Region 2 Vessel 2 14.6 5.1 
6 Myogenic Cells No PEC Ligated Region 2 Vessel 3 11.0 4.5 
6 Myogenic Cells No PEC Ligated Region 3 Vessel 1 18.0 5.0 
6 Myogenic Cells No PEC Ligated Region 3 Vessel 2 15.2 5.4 
6 Myogenic Cells No PEC Ligated Region 3 Vessel 3 15.4 5.5 
1 Vehicle PEC Ligated Region 1 Vessel 1 15.6 6.1 
1 Vehicle PEC Ligated Region 1 Vessel 2 13.3 5.9 
1 Vehicle PEC Ligated Region 1 Vessel 3 14.8 5.2 
1 Vehicle PEC Ligated Region 2 Vessel 1 14.9 4.7 
1 Vehicle PEC Ligated Region 2 Vessel 2 12.5 4.6 
1 Vehicle PEC Ligated Region 2 Vessel 3 7.6 4.4 
1 Vehicle PEC Ligated Region 3 Vessel 1 7.3 5.0 
1 Vehicle PEC Ligated Region 3 Vessel 2 7.6 5.0 
1 Vehicle PEC Ligated Region 3 Vessel 3 6.9 7.3 
2 Vehicle PEC Ligated Region 1 Vessel 1 6.8 4.6 
2 Vehicle PEC Ligated Region 1 Vessel 2 6.3 3.5 
2 Vehicle PEC Ligated Region 1 Vessel 3 4.5 5.1 
2 Vehicle PEC Ligated Region 2 Vessel 1 9.6 5.0 
2 Vehicle PEC Ligated Region 2 Vessel 2 9.2 4.6 
2 Vehicle PEC Ligated Region 2 Vessel 3 8.8 4.7 
2 Vehicle PEC Ligated Region 3 Vessel 1 9.5 3.9 
2 Vehicle PEC Ligated Region 3 Vessel 2 5.9 4.8 
2 Vehicle PEC Ligated Region 3 Vessel 3 8.4 5.5 
3 Vehicle No PEC Ligated Region 1 Vessel 1 11.7 7.4 
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3 Vehicle No PEC Ligated Region 1 Vessel 2 7.8 5.7 
3 Vehicle No PEC Ligated Region 1 Vessel 3 7.3 6.8 
3 Vehicle No PEC Ligated Region 2 Vessel 1 11.5 4.6 
3 Vehicle No PEC Ligated Region 2 Vessel 2 9.6 5.9 
3 Vehicle No PEC Ligated Region 2 Vessel 3 7.6 3.5 
3 Vehicle No PEC Ligated Region 3 Vessel 1 8.4 6.0 
3 Vehicle No PEC Ligated Region 3 Vessel 2 8.0 6.3 
3 Vehicle No PEC Ligated Region 3 Vessel 3 7.7 7.6 
4 Vehicle No PEC Ligated Region 1 Vessel 1   5.5 
4 Vehicle No PEC Ligated Region 1 Vessel 2   5.1 
4 Vehicle No PEC Ligated Region 1 Vessel 3   4.4 
4 Vehicle No PEC Ligated Region 2 Vessel 1 9.4 5.1 
4 Vehicle No PEC Ligated Region 2 Vessel 2 16.9 4.8 
4 Vehicle No PEC Ligated Region 2 Vessel 3 8.0 4.9 
4 Vehicle No PEC Ligated Region 3 Vessel 1 11.3 5.9 
4 Vehicle No PEC Ligated Region 3 Vessel 2 8.9 6.1 
4 Vehicle No PEC Ligated Region 3 Vessel 3 11.6 5.7 
5 Vehicle No PEC Ligated Region 1 Vessel 1 11.0 7.8 
5 Vehicle No PEC Ligated Region 1 Vessel 2 8.2 4.1 
5 Vehicle No PEC Ligated Region 1 Vessel 3 9.5 5.2 
5 Vehicle No PEC Ligated Region 2 Vessel 1 8.3 4.3 
5 Vehicle No PEC Ligated Region 2 Vessel 2 9.5 5.0 
5 Vehicle No PEC Ligated Region 2 Vessel 3 9.6 7.5 
5 Vehicle No PEC Ligated Region 3 Vessel 1 12.6 4.3 
5 Vehicle No PEC Ligated Region 3 Vessel 2 14.3 4.8 
5 Vehicle No PEC Ligated Region 3 Vessel 3 12.1 5.1 
6 Vehicle No PEC Ligated Region 1 Vessel 1 14.0 4.3 
6 Vehicle No PEC Ligated Region 1 Vessel 2 8.7 4.0 
6 Vehicle No PEC Ligated Region 1 Vessel 3 11.5 4.1 
6 Vehicle No PEC Ligated Region 2 Vessel 1 9.0 3.4 
6 Vehicle No PEC Ligated Region 2 Vessel 2 14.9 4.1 
6 Vehicle No PEC Ligated Region 2 Vessel 3 13.2 3.2 
6 Vehicle No PEC Ligated Region 3 Vessel 1 10.0 3.7 
6 Vehicle No PEC Ligated Region 3 Vessel 2 10.6 4.1 
6 Vehicle No PEC Ligated Region 3 Vessel 3 12.5 5.0 
1 Thrombin No PEC Ligated Region 1 Vessel 1 11.2 4.7 
1 Thrombin No PEC Ligated Region 1 Vessel 2 13.8 4.5 
1 Thrombin No PEC Ligated Region 1 Vessel 3 15.0 5.6 
1 Thrombin No PEC Ligated Region 2 Vessel 1 22.3 3.5 
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1 Thrombin No PEC Ligated Region 2 Vessel 2 15.8 3.3 
1 Thrombin No PEC Ligated Region 2 Vessel 3 11.2 4.5 
1 Thrombin No PEC Ligated Region 3 Vessel 1 12.1 5.0 
1 Thrombin No PEC Ligated Region 3 Vessel 2 12.9 4.3 
1 Thrombin No PEC Ligated Region 3 Vessel 3 15.4 4.5 
2 Thrombin PEC Ligated Region 1 Vessel 1 11.3 4.1 
2 Thrombin PEC Ligated Region 1 Vessel 2 13.8 4.4 
2 Thrombin PEC Ligated Region 1 Vessel 3 9.7 4.2 
2 Thrombin PEC Ligated Region 2 Vessel 1 16.2 5.9 
2 Thrombin PEC Ligated Region 2 Vessel 2 11.5 4.8 
2 Thrombin PEC Ligated Region 2 Vessel 3 13.3 4.9 
2 Thrombin PEC Ligated Region 3 Vessel 1 9.0 4.0 
2 Thrombin PEC Ligated Region 3 Vessel 2 11.7 4.1 
2 Thrombin PEC Ligated Region 3 Vessel 3 8.6 4.6 
3 Thrombin No PEC Ligated Region 1 Vessel 1 15.7 4.8 
3 Thrombin No PEC Ligated Region 1 Vessel 2 14.4 5.1 
3 Thrombin No PEC Ligated Region 1 Vessel 3 16.7 5.0 
3 Thrombin No PEC Ligated Region 2 Vessel 1 10.3 4.7 
3 Thrombin No PEC Ligated Region 2 Vessel 2 10.1 5.2 
3 Thrombin No PEC Ligated Region 2 Vessel 3 11.0 5.2 
3 Thrombin No PEC Ligated Region 3 Vessel 1 11.5 4.5 
3 Thrombin No PEC Ligated Region 3 Vessel 2 9.2 4.9 
3 Thrombin No PEC Ligated Region 3 Vessel 3 7.0 4.9 
4 Thrombin No PEC Ligated Region 1 Vessel 1 14.2 5.2 
4 Thrombin No PEC Ligated Region 1 Vessel 2 11.8 5.3 
4 Thrombin No PEC Ligated Region 1 Vessel 3 14.1 3.7 
4 Thrombin No PEC Ligated Region 2 Vessel 1 14.9 3.8 
4 Thrombin No PEC Ligated Region 2 Vessel 2 11.9 5.6 
4 Thrombin No PEC Ligated Region 2 Vessel 3 11.8 4.9 
4 Thrombin No PEC Ligated Region 3 Vessel 1 15.0 4.6 
4 Thrombin No PEC Ligated Region 3 Vessel 2 14.1 5.5 
4 Thrombin No PEC Ligated Region 3 Vessel 3 19.2 4.1 
5 Thrombin PEC Ligated Region 1 Vessel 1 7.5 4.5 
5 Thrombin PEC Ligated Region 1 Vessel 2 5.0 5.5 
5 Thrombin PEC Ligated Region 1 Vessel 3 6.5 3.0 
5 Thrombin PEC Ligated Region 2 Vessel 1 8.8 5.1 
5 Thrombin PEC Ligated Region 2 Vessel 2 7.3 2.6 
5 Thrombin PEC Ligated Region 2 Vessel 3 6.8 4.8 
5 Thrombin PEC Ligated Region 3 Vessel 1 7.3 4.5 
 69 
5 Thrombin PEC Ligated Region 3 Vessel 2 8.5 5.5 
5 Thrombin PEC Ligated Region 3 Vessel 3 10.5 4.7 
1 Ligation Only PEC Ligated Region 1 Vessel 1 13.2 4.0 
1 Ligation Only PEC Ligated Region 1 Vessel 2 14.6 4.3 
1 Ligation Only PEC Ligated Region 1 Vessel 3 4.6 3.8 
1 Ligation Only PEC Ligated Region 2 Vessel 1 7.7 3.3 
1 Ligation Only PEC Ligated Region 2 Vessel 2 6.9 4.6 
1 Ligation Only PEC Ligated Region 2 Vessel 3 9.1 4.0 
1 Ligation Only PEC Ligated Region 3 Vessel 1 6.4 5.9 
1 Ligation Only PEC Ligated Region 3 Vessel 2 7.0 4.1 
1 Ligation Only PEC Ligated Region 3 Vessel 3 4.3 3.2 
2 Ligation Only No PEC Ligated Region 1 Vessel 1 12.1 4.9 
2 Ligation Only No PEC Ligated Region 1 Vessel 2 13.5 5.9 
2 Ligation Only No PEC Ligated Region 1 Vessel 3 14.6 4.3 
2 Ligation Only No PEC Ligated Region 2 Vessel 1 13.4 6.2 
2 Ligation Only No PEC Ligated Region 2 Vessel 2 12.3 5.6 
2 Ligation Only No PEC Ligated Region 2 Vessel 3 11.5 3.7 
2 Ligation Only No PEC Ligated Region 3 Vessel 1 9.0 3.5 
2 Ligation Only No PEC Ligated Region 3 Vessel 2 9.3 4.4 
2 Ligation Only No PEC Ligated Region 3 Vessel 3 6.4 4.9 
3 Ligation Only No PEC Ligated Region 1 Vessel 1 15.2 5.1 
3 Ligation Only No PEC Ligated Region 1 Vessel 2 10.9 5.2 
3 Ligation Only No PEC Ligated Region 1 Vessel 3 7.8 5.2 
3 Ligation Only No PEC Ligated Region 2 Vessel 1 13.0 6.0 
3 Ligation Only No PEC Ligated Region 2 Vessel 2 15.2 6.1 
3 Ligation Only No PEC Ligated Region 2 Vessel 3 10.1 4.8 
3 Ligation Only No PEC Ligated Region 3 Vessel 1 12.1 7.0 
3 Ligation Only No PEC Ligated Region 3 Vessel 2 10.6 7.0 
3 Ligation Only No PEC Ligated Region 3 Vessel 3 10.5 5.8 
4 Ligation Only No PEC Ligated Region 1 Vessel 1 14.7 5.4 
4 Ligation Only No PEC Ligated Region 1 Vessel 2 11.0 4.8 
4 Ligation Only No PEC Ligated Region 1 Vessel 3 10.6 5.6 
4 Ligation Only No PEC Ligated Region 2 Vessel 1 9.6 6.1 
4 Ligation Only No PEC Ligated Region 2 Vessel 2 13.3 6.3 
4 Ligation Only No PEC Ligated Region 2 Vessel 3 14.2 5.8 
4 Ligation Only No PEC Ligated Region 3 Vessel 1 17.4 3.8 
4 Ligation Only No PEC Ligated Region 3 Vessel 2 15.5 5.9 
4 Ligation Only No PEC Ligated Region 3 Vessel 3 10.3 4.8 
5 Ligation Only PEC Ligated Region 1 Vessel 1 6.4 5.1 
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5 Ligation Only PEC Ligated Region 1 Vessel 2 9.6 5.4 
5 Ligation Only PEC Ligated Region 1 Vessel 3 5.2 5.2 
5 Ligation Only PEC Ligated Region 2 Vessel 1 10.6 4.5 
5 Ligation Only PEC Ligated Region 2 Vessel 2 8.1 5.0 
5 Ligation Only PEC Ligated Region 2 Vessel 3 7.7 4.2 
5 Ligation Only PEC Ligated Region 3 Vessel 1 6.7 5.0 
5 Ligation Only PEC Ligated Region 3 Vessel 2 9.0 4.9 
5 Ligation Only PEC Ligated Region 3 Vessel 3 8.9 6.2 
1 Myogenic Cells PEC Sham Region 1 Vessel 1 N/A 4.3 
1 Myogenic Cells PEC Sham Region 1 Vessel 2 N/A 4.5 
1 Myogenic Cells PEC Sham Region 1 Vessel 3 N/A 4.8 
1 Myogenic Cells PEC Sham Region 2 Vessel 1 N/A 7.1 
1 Myogenic Cells PEC Sham Region 2 Vessel 2 N/A 4.8 
1 Myogenic Cells PEC Sham Region 2 Vessel 3 N/A 7.2 
1 Myogenic Cells PEC Sham Region 3 Vessel 1 N/A 4.5 
1 Myogenic Cells PEC Sham Region 3 Vessel 2 N/A 5.5 
1 Myogenic Cells PEC Sham Region 3 Vessel 3 N/A 5.2 
2 Myogenic Cells No PEC Sham Region 1 Vessel 1 N/A 6.0 
2 Myogenic Cells No PEC Sham Region 1 Vessel 2 N/A 4.6 
2 Myogenic Cells No PEC Sham Region 1 Vessel 3 N/A 5.7 
2 Myogenic Cells No PEC Sham Region 2 Vessel 1 N/A 5.1 
2 Myogenic Cells No PEC Sham Region 2 Vessel 2 N/A 4.0 
2 Myogenic Cells No PEC Sham Region 2 Vessel 3 N/A 4.1 
2 Myogenic Cells No PEC Sham Region 3 Vessel 1 N/A 4.2 
2 Myogenic Cells No PEC Sham Region 3 Vessel 2 N/A 4.3 
2 Myogenic Cells No PEC Sham Region 3 Vessel 3 N/A 5.0 
3 Myogenic Cells PEC Sham Region 1 Vessel 1 N/A 5.0 
3 Myogenic Cells PEC Sham Region 1 Vessel 2 N/A 4.6 
3 Myogenic Cells PEC Sham Region 1 Vessel 3 N/A 4.4 
3 Myogenic Cells PEC Sham Region 2 Vessel 1 N/A 4.7 
3 Myogenic Cells PEC Sham Region 2 Vessel 2 N/A 4.6 
3 Myogenic Cells PEC Sham Region 2 Vessel 3 N/A 4.0 
3 Myogenic Cells PEC Sham Region 3 Vessel 1 N/A 4.7 
3 Myogenic Cells PEC Sham Region 3 Vessel 2 N/A 4.4 
3 Myogenic Cells PEC Sham Region 3 Vessel 3 N/A 3.8 
4 Myogenic Cells No PEC Sham Region 1 Vessel 1 N/A 4.2 
4 Myogenic Cells No PEC Sham Region 1 Vessel 2 N/A 4.8 
4 Myogenic Cells No PEC Sham Region 1 Vessel 3 N/A 4.1 
4 Myogenic Cells No PEC Sham Region 2 Vessel 1 N/A 4.9 
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4 Myogenic Cells No PEC Sham Region 2 Vessel 2 N/A 5.7 
4 Myogenic Cells No PEC Sham Region 2 Vessel 3 N/A 4.4 
4 Myogenic Cells No PEC Sham Region 3 Vessel 1 N/A 5.9 
4 Myogenic Cells No PEC Sham Region 3 Vessel 2 N/A 5.5 
4 Myogenic Cells No PEC Sham Region 3 Vessel 3 N/A 5.3 
5 Myogenic Cells No PEC Sham Region 1 Vessel 1 N/A 4.4 
5 Myogenic Cells No PEC Sham Region 1 Vessel 2 N/A 4.2 
5 Myogenic Cells No PEC Sham Region 1 Vessel 3 N/A 3.9 
5 Myogenic Cells No PEC Sham Region 2 Vessel 1 N/A 5.8 
5 Myogenic Cells No PEC Sham Region 2 Vessel 2 N/A 5.9 
5 Myogenic Cells No PEC Sham Region 2 Vessel 3 N/A 5.4 
5 Myogenic Cells No PEC Sham Region 3 Vessel 1 N/A 6.4 
5 Myogenic Cells No PEC Sham Region 3 Vessel 2 N/A 4.7 
5 Myogenic Cells No PEC Sham Region 3 Vessel 3 N/A 5.0 
6 Myogenic Cells No PEC Sham Region 1 Vessel 1 N/A 5.6 
6 Myogenic Cells No PEC Sham Region 1 Vessel 2 N/A 5.1 
6 Myogenic Cells No PEC Sham Region 1 Vessel 3 N/A 4.7 
6 Myogenic Cells No PEC Sham Region 2 Vessel 1 N/A 5.6 
6 Myogenic Cells No PEC Sham Region 2 Vessel 2 N/A 5.3 
6 Myogenic Cells No PEC Sham Region 2 Vessel 3 N/A 6.0 
6 Myogenic Cells No PEC Sham Region 3 Vessel 1 N/A 5.5 
6 Myogenic Cells No PEC Sham Region 3 Vessel 2 N/A 4.7 
6 Myogenic Cells No PEC Sham Region 3 Vessel 3 N/A 4.4 
1 Vehicle PEC Sham Region 1 Vessel 1 N/A 4.2 
1 Vehicle PEC Sham Region 1 Vessel 2 N/A 3.6 
1 Vehicle PEC Sham Region 1 Vessel 3 N/A 3.9 
1 Vehicle PEC Sham Region 2 Vessel 1 N/A 4.6 
1 Vehicle PEC Sham Region 2 Vessel 2 N/A 5.3 
1 Vehicle PEC Sham Region 2 Vessel 3 N/A 5.8 
1 Vehicle PEC Sham Region 3 Vessel 1 N/A 5.5 
1 Vehicle PEC Sham Region 3 Vessel 2 N/A 5.0 
1 Vehicle PEC Sham Region 3 Vessel 3 N/A 5.0 
2 Vehicle PEC Sham Region 1 Vessel 1 N/A 5.6 
2 Vehicle PEC Sham Region 1 Vessel 2 N/A 5.0 
2 Vehicle PEC Sham Region 1 Vessel 3 N/A 4.3 
2 Vehicle PEC Sham Region 2 Vessel 1 N/A 4.1 
2 Vehicle PEC Sham Region 2 Vessel 2 N/A 4.3 
2 Vehicle PEC Sham Region 2 Vessel 3 N/A 4.4 
2 Vehicle PEC Sham Region 3 Vessel 1 N/A 4.0 
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2 Vehicle PEC Sham Region 3 Vessel 2 N/A 4.6 
2 Vehicle PEC Sham Region 3 Vessel 3 N/A 4.9 
3 Vehicle No PEC Sham Region 1 Vessel 1 N/A 4.1 
3 Vehicle No PEC Sham Region 1 Vessel 2 N/A 5.0 
3 Vehicle No PEC Sham Region 1 Vessel 3 N/A 3.9 
3 Vehicle No PEC Sham Region 2 Vessel 1 N/A 6.1 
3 Vehicle No PEC Sham Region 2 Vessel 2 N/A 6.3 
3 Vehicle No PEC Sham Region 2 Vessel 3 N/A 4.6 
3 Vehicle No PEC Sham Region 3 Vessel 1 N/A 3.5 
3 Vehicle No PEC Sham Region 3 Vessel 2 N/A 6.4 
3 Vehicle No PEC Sham Region 3 Vessel 3 N/A 5.9 
4 Vehicle No PEC Sham Region 1 Vessel 1 N/A 5.4 
4 Vehicle No PEC Sham Region 1 Vessel 2 N/A 5.6 
4 Vehicle No PEC Sham Region 1 Vessel 3 N/A 5.1 
4 Vehicle No PEC Sham Region 2 Vessel 1 N/A 5.4 
4 Vehicle No PEC Sham Region 2 Vessel 2 N/A 7.5 
4 Vehicle No PEC Sham Region 2 Vessel 3 N/A 5.6 
4 Vehicle No PEC Sham Region 3 Vessel 1 N/A 4.8 
4 Vehicle No PEC Sham Region 3 Vessel 2 N/A 6.2 
4 Vehicle No PEC Sham Region 3 Vessel 3 N/A 4.8 
5 Vehicle No PEC Sham Region 1 Vessel 1 N/A 4.8 
5 Vehicle No PEC Sham Region 1 Vessel 2 N/A 6.3 
5 Vehicle No PEC Sham Region 1 Vessel 3 N/A 4.9 
5 Vehicle No PEC Sham Region 2 Vessel 1 N/A 6.1 
5 Vehicle No PEC Sham Region 2 Vessel 2 N/A 5.5 
5 Vehicle No PEC Sham Region 2 Vessel 3 N/A 5.4 
5 Vehicle No PEC Sham Region 3 Vessel 1 N/A 5.8 
5 Vehicle No PEC Sham Region 3 Vessel 2 N/A 6.0 
5 Vehicle No PEC Sham Region 3 Vessel 3 N/A 6.0 
6 Vehicle No PEC Sham Region 1 Vessel 1 N/A 4.9 
6 Vehicle No PEC Sham Region 1 Vessel 2 N/A 4.5 
6 Vehicle No PEC Sham Region 1 Vessel 3 N/A 4.8 
6 Vehicle No PEC Sham Region 2 Vessel 1 N/A 6.1 
6 Vehicle No PEC Sham Region 2 Vessel 2 N/A 4.5 
6 Vehicle No PEC Sham Region 2 Vessel 3 N/A 4.4 
6 Vehicle No PEC Sham Region 3 Vessel 1 N/A 5.3 
6 Vehicle No PEC Sham Region 3 Vessel 2 N/A 5.0 
6 Vehicle No PEC Sham Region 3 Vessel 3 N/A 4.1 
1 Thrombin No PEC Sham Region 1 Vessel 1 N/A 5.8 
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1 Thrombin No PEC Sham Region 1 Vessel 2 N/A 4.8 
1 Thrombin No PEC Sham Region 1 Vessel 3 N/A 4.4 
1 Thrombin No PEC Sham Region 2 Vessel 1 N/A 6.6 
1 Thrombin No PEC Sham Region 2 Vessel 2 N/A 6.3 
1 Thrombin No PEC Sham Region 2 Vessel 3 N/A 5.0 
1 Thrombin No PEC Sham Region 3 Vessel 1 N/A 4.4 
1 Thrombin No PEC Sham Region 3 Vessel 2 N/A 4.9 
1 Thrombin No PEC Sham Region 3 Vessel 3 N/A 4.9 
2 Thrombin PEC Sham Region 1 Vessel 1 N/A 5.2 
2 Thrombin PEC Sham Region 1 Vessel 2 N/A 5.2 
2 Thrombin PEC Sham Region 1 Vessel 3 N/A 4.3 
2 Thrombin PEC Sham Region 2 Vessel 1 N/A 3.9 
2 Thrombin PEC Sham Region 2 Vessel 2 N/A 5.5 
2 Thrombin PEC Sham Region 2 Vessel 3 N/A 4.4 
2 Thrombin PEC Sham Region 3 Vessel 1 N/A 7.0 
2 Thrombin PEC Sham Region 3 Vessel 2 N/A 7.1 
2 Thrombin PEC Sham Region 3 Vessel 3 N/A 5.0 
3 Thrombin No PEC Sham Region 1 Vessel 1 N/A 5.9 
3 Thrombin No PEC Sham Region 1 Vessel 2 N/A 4.9 
3 Thrombin No PEC Sham Region 1 Vessel 3 N/A 5.2 
3 Thrombin No PEC Sham Region 2 Vessel 1 N/A 3.8 
3 Thrombin No PEC Sham Region 2 Vessel 2 N/A 4.5 
3 Thrombin No PEC Sham Region 2 Vessel 3 N/A 5.6 
3 Thrombin No PEC Sham Region 3 Vessel 1 N/A 4.1 
3 Thrombin No PEC Sham Region 3 Vessel 2 N/A 5.2 
3 Thrombin No PEC Sham Region 3 Vessel 3 N/A 3.7 
4 Thrombin No PEC Sham Region 1 Vessel 1 N/A 4.8 
4 Thrombin No PEC Sham Region 1 Vessel 2 N/A 4.7 
4 Thrombin No PEC Sham Region 1 Vessel 3 N/A 5.5 
4 Thrombin No PEC Sham Region 2 Vessel 1 N/A 4.3 
4 Thrombin No PEC Sham Region 2 Vessel 2 N/A 5.6 
4 Thrombin No PEC Sham Region 2 Vessel 3 N/A 4.6 
4 Thrombin No PEC Sham Region 3 Vessel 1 N/A 4.6 
4 Thrombin No PEC Sham Region 3 Vessel 2 N/A 4.7 
4 Thrombin No PEC Sham Region 3 Vessel 3 N/A 4.2 
5 Thrombin PEC Sham Region 1 Vessel 1 N/A 5.2 
5 Thrombin PEC Sham Region 1 Vessel 2 N/A 4.0 
5 Thrombin PEC Sham Region 1 Vessel 3 N/A 5.0 
5 Thrombin PEC Sham Region 2 Vessel 1 N/A 5.3 
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5 Thrombin PEC Sham Region 2 Vessel 2 N/A 3.7 
5 Thrombin PEC Sham Region 2 Vessel 3 N/A 4.1 
5 Thrombin PEC Sham Region 3 Vessel 1 N/A 4.7 
5 Thrombin PEC Sham Region 3 Vessel 2 N/A 4.7 
5 Thrombin PEC Sham Region 3 Vessel 3 N/A 4.4 
1 Ligation Only PEC Sham Region 1 Vessel 1 N/A 5.2 
1 Ligation Only PEC Sham Region 1 Vessel 2 N/A 5.0 
1 Ligation Only PEC Sham Region 1 Vessel 3 N/A 4.6 
1 Ligation Only PEC Sham Region 2 Vessel 1 N/A 6.0 
1 Ligation Only PEC Sham Region 2 Vessel 2 N/A 6.6 
1 Ligation Only PEC Sham Region 2 Vessel 3 N/A 4.9 
1 Ligation Only PEC Sham Region 3 Vessel 1 N/A 4.9 
1 Ligation Only PEC Sham Region 3 Vessel 2 N/A 4.2 
1 Ligation Only PEC Sham Region 3 Vessel 3 N/A 6.2 
2 Ligation Only No PEC Sham Region 1 Vessel 1 N/A 4.3 
2 Ligation Only No PEC Sham Region 1 Vessel 2 N/A 5.3 
2 Ligation Only No PEC Sham Region 1 Vessel 3 N/A 5.8 
2 Ligation Only No PEC Sham Region 2 Vessel 1 N/A 5.7 
2 Ligation Only No PEC Sham Region 2 Vessel 2 N/A 5.7 
2 Ligation Only No PEC Sham Region 2 Vessel 3 N/A 5.0 
2 Ligation Only No PEC Sham Region 3 Vessel 1 N/A 5.2 
2 Ligation Only No PEC Sham Region 3 Vessel 2 N/A 6.7 
2 Ligation Only No PEC Sham Region 3 Vessel 3 N/A 8.4 
3 Ligation Only No PEC Sham Region 1 Vessel 1 N/A 3.9 
3 Ligation Only No PEC Sham Region 1 Vessel 2 N/A 5.5 
3 Ligation Only No PEC Sham Region 1 Vessel 3 N/A 4.8 
3 Ligation Only No PEC Sham Region 2 Vessel 1 N/A 5.6 
3 Ligation Only No PEC Sham Region 2 Vessel 2 N/A 5.7 
3 Ligation Only No PEC Sham Region 2 Vessel 3 N/A 5.6 
3 Ligation Only No PEC Sham Region 3 Vessel 1 N/A 5.4 
3 Ligation Only No PEC Sham Region 3 Vessel 2 N/A 4.8 
3 Ligation Only No PEC Sham Region 3 Vessel 3 N/A 6.1 
4 Ligation Only No PEC Sham Region 1 Vessel 1 N/A 4.9 
4 Ligation Only No PEC Sham Region 1 Vessel 2 N/A 5.2 
4 Ligation Only No PEC Sham Region 1 Vessel 3 N/A 5.6 
4 Ligation Only No PEC Sham Region 2 Vessel 1 N/A 4.9 
4 Ligation Only No PEC Sham Region 2 Vessel 2 N/A 5.1 
4 Ligation Only No PEC Sham Region 2 Vessel 3 N/A 7.1 
4 Ligation Only No PEC Sham Region 3 Vessel 1 N/A 4.3 
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4 Ligation Only No PEC Sham Region 3 Vessel 2 N/A 5.9 
4 Ligation Only No PEC Sham Region 3 Vessel 3 N/A 4.6 
5 Ligation Only PEC Sham Region 1 Vessel 1 N/A 4.0 
5 Ligation Only PEC Sham Region 1 Vessel 2 N/A 4.9 
5 Ligation Only PEC Sham Region 1 Vessel 3 N/A 5.0 
5 Ligation Only PEC Sham Region 2 Vessel 1 N/A 6.7 
5 Ligation Only PEC Sham Region 2 Vessel 2 N/A 5.7 
5 Ligation Only PEC Sham Region 2 Vessel 3 N/A 6.3 
5 Ligation Only PEC Sham Region 3 Vessel 1 N/A 4.9 
5 Ligation Only PEC Sham Region 3 Vessel 2 N/A 5.9 
5 Ligation Only PEC Sham Region 3 Vessel 3 N/A 6.2 
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Cell Transplantation Maximum Diameter Data 
Replicate Treatment Muscle 
Max α-SMA 
Vessel Diameter 
(µm) 
Number of Vessels in 
Region with Max 
Diameter Vessel 
1 Myogenic Cells Ligated PEC PEC 
2 Myogenic Cells Ligated 44.1 5 
3 Myogenic Cells Ligated PEC PEC 
4 Myogenic Cells Ligated 17.7 12 
5 Myogenic Cells Ligated 28.7 8 
6 Myogenic Cells Ligated 28.9 9 
1 Vehicle Ligated PEC PEC 
2 Vehicle Ligated PEC PEC 
3 Vehicle Ligated 9.3 15 
4 Vehicle Ligated 18.0 12 
5 Vehicle Ligated 23.6 16 
6 Vehicle Ligated 20.9 16 
1 Thrombin Ligated 25.0 10 
2 Thrombin Ligated PEC PEC 
3 Thrombin Ligated 23.0 8 
4 Thrombin Ligated 35.6 11 
5 Thrombin Ligated PEC PEC 
1 Ligation Only Ligated PEC PEC 
2 Ligation Only Ligated 19.1 12 
3 Ligation Only Ligated 15.2 15 
4 Ligation Only Ligated 22.5 14 
5 Ligation Only Ligated PEC PEC 
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Cell Transplantation CD68 Data 
Replicate Treatment Muscle Region 
Overall 
CD68 Cell 
Count 
Vessel 
Associated 
CD68 Cells 
1 Myogenic Cells Ligated Region 1 19 14 
1 Myogenic Cells Ligated Region 2 15 11 
1 Myogenic Cells Ligated Region 3 16 16 
2 Myogenic Cells Ligated Region 1 15 21 
2 Myogenic Cells Ligated Region 2 19 24 
2 Myogenic Cells Ligated Region 3 16 15 
3 Myogenic Cells Ligated Region 1 15 15 
3 Myogenic Cells Ligated Region 2 14 13 
3 Myogenic Cells Ligated Region 3 14 18 
4 Myogenic Cells Ligated Region 1 14 20 
4 Myogenic Cells Ligated Region 2 14 14 
4 Myogenic Cells Ligated Region 3 15 20 
5 Myogenic Cells Ligated Region 1 15 23 
5 Myogenic Cells Ligated Region 2 20 16 
5 Myogenic Cells Ligated Region 3 19 18 
6 Myogenic Cells Ligated Region 1 16 16 
6 Myogenic Cells Ligated Region 2 17 13 
6 Myogenic Cells Ligated Region 3 15 18 
1 Vehicle Ligated Region 1 15 16 
1 Vehicle Ligated Region 2 15 16 
1 Vehicle Ligated Region 3 16 17 
2 Vehicle Ligated Region 1 16 14 
2 Vehicle Ligated Region 2 14 16 
2 Vehicle Ligated Region 3 15 12 
3 Vehicle Ligated Region 1 18 14 
3 Vehicle Ligated Region 2 21 20 
3 Vehicle Ligated Region 3 15 12 
4 Vehicle Ligated Region 1 14 12 
4 Vehicle Ligated Region 2 17 13 
4 Vehicle Ligated Region 3 17 13 
5 Vehicle Ligated Region 1 16 17 
5 Vehicle Ligated Region 2 15 19 
5 Vehicle Ligated Region 3 17 11 
6 Vehicle Ligated Region 1 14 18 
6 Vehicle Ligated Region 2 14 11 
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6 Vehicle Ligated Region 3 15 12 
1 Thrombin Ligated Region 1 19 14 
1 Thrombin Ligated Region 2 16 15 
1 Thrombin Ligated Region 3 17 15 
2 Thrombin Ligated Region 1 15 16 
2 Thrombin Ligated Region 2 14 15 
2 Thrombin Ligated Region 3 16 15 
3 Thrombin Ligated Region 1 10 12 
3 Thrombin Ligated Region 2 16 20 
3 Thrombin Ligated Region 3 16 16 
4 Thrombin Ligated Region 1 16 19 
4 Thrombin Ligated Region 2 16 19 
4 Thrombin Ligated Region 3 16 22 
5 Thrombin Ligated Region 1 14 13 
5 Thrombin Ligated Region 2 15 17 
5 Thrombin Ligated Region 3 14 13 
1 Ligation Only Ligated Region 1 15 16 
1 Ligation Only Ligated Region 2 18 15 
1 Ligation Only Ligated Region 3 17 17 
2 Ligation Only Ligated Region 1 19 20 
2 Ligation Only Ligated Region 2 13 17 
2 Ligation Only Ligated Region 3 17 18 
3 Ligation Only Ligated Region 1 15 19 
3 Ligation Only Ligated Region 2 15 22 
3 Ligation Only Ligated Region 3 15 20 
4 Ligation Only Ligated Region 1 13 19 
4 Ligation Only Ligated Region 2 16 20 
4 Ligation Only Ligated Region 3 13 16 
5 Ligation Only Ligated Region 1 15 12 
5 Ligation Only Ligated Region 2 15 12 
5 Ligation Only Ligated Region 3 16 14 
1 Myogenic Cells Sham Region 1 8 N/A 
1 Myogenic Cells Sham Region 2 7 N/A 
1 Myogenic Cells Sham Region 3 10 N/A 
2 Myogenic Cells Sham Region 1 5 N/A 
2 Myogenic Cells Sham Region 2 7 N/A 
2 Myogenic Cells Sham Region 3 7 N/A 
3 Myogenic Cells Sham Region 1 7 N/A 
3 Myogenic Cells Sham Region 2 8 N/A 
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3 Myogenic Cells Sham Region 3 8 N/A 
4 Myogenic Cells Sham Region 1 8 N/A 
4 Myogenic Cells Sham Region 2 7 N/A 
4 Myogenic Cells Sham Region 3 6 N/A 
5 Myogenic Cells Sham Region 1 7 N/A 
5 Myogenic Cells Sham Region 2 8 N/A 
5 Myogenic Cells Sham Region 3 8 N/A 
6 Myogenic Cells Sham Region 1 6 N/A 
6 Myogenic Cells Sham Region 2 6 N/A 
6 Myogenic Cells Sham Region 3 6 N/A 
1 Vehicle Sham Region 1 7 N/A 
1 Vehicle Sham Region 2 7 N/A 
1 Vehicle Sham Region 3 6 N/A 
2 Vehicle Sham Region 1 8 N/A 
2 Vehicle Sham Region 2 11 N/A 
2 Vehicle Sham Region 3 8 N/A 
3 Vehicle Sham Region 1 9 N/A 
3 Vehicle Sham Region 2 8 N/A 
3 Vehicle Sham Region 3 6 N/A 
4 Vehicle Sham Region 1 6 N/A 
4 Vehicle Sham Region 2 7 N/A 
4 Vehicle Sham Region 3 6 N/A 
5 Vehicle Sham Region 1 6 N/A 
5 Vehicle Sham Region 2 6 N/A 
5 Vehicle Sham Region 3 6 N/A 
6 Vehicle Sham Region 1 7 N/A 
6 Vehicle Sham Region 2 6 N/A 
6 Vehicle Sham Region 3 8 N/A 
1 Thrombin Sham Region 1 7 N/A 
1 Thrombin Sham Region 2 6 N/A 
1 Thrombin Sham Region 3 7 N/A 
2 Thrombin Sham Region 1 10 N/A 
2 Thrombin Sham Region 2 9 N/A 
2 Thrombin Sham Region 3 6 N/A 
3 Thrombin Sham Region 1 6 N/A 
3 Thrombin Sham Region 2 7 N/A 
3 Thrombin Sham Region 3 8 N/A 
4 Thrombin Sham Region 1 7 N/A 
4 Thrombin Sham Region 2 6 N/A 
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4 Thrombin Sham Region 3 7 N/A 
5 Thrombin Sham Region 1 6 N/A 
5 Thrombin Sham Region 2 6 N/A 
5 Thrombin Sham Region 3 7 N/A 
1 Ligation Only Sham Region 1 8 N/A 
1 Ligation Only Sham Region 2 9 N/A 
1 Ligation Only Sham Region 3 8 N/A 
2 Ligation Only Sham Region 1 10 N/A 
2 Ligation Only Sham Region 2 6 N/A 
2 Ligation Only Sham Region 3 5 N/A 
3 Ligation Only Sham Region 1 5 N/A 
3 Ligation Only Sham Region 2 6 N/A 
3 Ligation Only Sham Region 3 5 N/A 
4 Ligation Only Sham Region 1 7 N/A 
4 Ligation Only Sham Region 2 7 N/A 
4 Ligation Only Sham Region 3 7 N/A 
5 Ligation Only Sham Region 1 7 N/A 
5 Ligation Only Sham Region 2 8 N/A 
5 Ligation Only Sham Region 3 7 N/A 
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Appendix D: Statistics 
Sample Independent t-test Outputs  
Male versus Female α-SMA vessel count 
 
 
 
Male versus Female α-SMA vessel diameter 
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Sample One-Way ANOVAs with Tukey comparisons 
 
Cell Transplantation α-SMA vessel counts 
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Cell Transplantation Sham Vessel Count 
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Cell Transplantation Total Vessel Count 
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Cell Transplantation α-SMA Vessel Diameters 
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Cell Transplantation Mice without a PEC Vessel Count 
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Cell Transplantation Vessel Count in the Region with the Maximum Diameter ACC 
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 Cell Transplantation Maximum Diameter Vessel 
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Cell Transplantation Overall CD68) 
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Cell Transplantation Vessel Associated CD68 Cells 
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Mice with a PEC Sample Size Power Analysis Graph 
 
 
Mice without a PEC Sample Size Power Analysis Graph 
 
